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Abstract 
 
 
For years statistical analysis has been applied to different areas 
of the natural and applied sciences to determine the degree of 
confidence that can be placed in research results. 
 
This work is a good example of how statistics can be applied to 
toxicology to enable conclusions and inferences to be made 
about important areas of interest such as the drugs and driving 
situation in New Zealand. 
 
Two thousand uninjured drivers (Study 1) who had provided an 
evidential blood alcohol sample, were also tested for cannabis, 
methamphetamine, benzodiazepines and morphine to determine 
the incidence of drug use by drinking drivers. 
  
To determine the proportion of drivers killed in car crashes who 
had used drugs and/or alcohol, two hundred and twenty nine 
fatally injured drivers (Study 2) were tested for alcohol, 
cannabis, methamphetamine, morphine, benzodiazepines and 
neutral and basic medicinal drugs that might have an effect on 
driving performance.  
 
Alcohol, cannabis and their combination were found to be the 
most prevalent drugs used by drivers.  
 iv
 
The analytical methodologies used were developed and validated 
by the Institute of Environmental Science and Research Ltd., 
where this work was carried out. These techniques involved 
liquid-liquid and liquid-solid extractions, immunoassays and 
chromatographic techniques for screening and confirmation 
assays. The statistical analysis of the results was done under the 
supervision of the Institute’s biostatistician. 
 
An approach to cannabis culpability, intended to elucidate the 
role of this drug in car crashes, was applied to the Study 2 
results. The number of samples collected during one year of 
research was not sufficient to enable statistically robust 
conclusions to be drawn. 
 
Cannabis use is illegal in New Zealand but drugs (different to 
alcohol) are not regularly tested at the roadside. This work as 
part of a cross-departmental project titled “Drinking and drugged 
driver control: delineating the problem” is expected to support 
the establishment of strategies designed to reduce the road toll 
and possibly include the screening of non-alcohol drugs in 
serious and fatally injured drivers. 
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1.   Introduction 
 
 
 
Every year approximately 1.2 million people die in the world as a 
consequence of car accidents and 50 million more are injured 
[1]. The cost that road accidents represents for governments 
worldwide has been estimated1 as a raw value of US$ 518 
billion, of which, US$ 453 billion is contributed by highly 
motorised countries2 [1,2]. These figures bring along health, 
psychological, social and economic consequences that prompt 
governments to implement improved strategies and measures to 
ensure a more promising forecast for the next 20 years. 
 
A first step in the establishment of prevention measures is the 
identification of risk factors that can influence the occurrence of 
road accidents and their severity.  
 
New Zealand is one of the most highly motorised countries in the 
world. The Land Transport Safety Authority (LTSA) identified 
some possible factors that have contributed to fatal crashes in 
the country [3]: 
 
 Driver/rider control factors: alcohol or drugs, too fast for 
conditions, control loss. 
 Vehicle conflict factors: failure to give way, to stop, to 
notice cars slowing. 
 General driver factors: inexperience, fatigue, racing. 
 General person factors: illness and disability. 
 Vehicle factors: brakes, steering, tyres, and mechanical. 
 Pedestrian factors: walking along road. 
                                                 
1  Estimates were based on each country’s gross national product (GNP), assuming the annual 
cost of road crashes for developing countries is 1%, for transitional countries 1.5% and highly 
motorised countries 2% [2]. 
2  North America, Australia, New Zealand, Japan and Western Europe [1]. 
 2
 Road factors: surface, obstructions, markings. 
 Miscellaneous factors: weather, animals. 
 
As can be expected, alcohol and drugs are contributory factors to 
road fatality statistics (31% of fatal cases) [3]. The effect of 
alcohol on driving impairment has been widely studied and the 
degree of impairment is found to be directly related to the blood 
alcohol concentration (BAC) [4-8]. The effects are evident on 
performance skills such as coordination, attention, decision 
making, reaction time and risk taking behaviour [4]. However, 
the role of most recreational and medicinal drugs in the same 
context has been less thoroughly studied because of its 
challenging characteristics: not all substances maintain a direct 
relationship between concentration and effect. This lack of 
correlation is very evident in the case of tetrahydrocannabinol 
(THC) [9,10]. 
 
Knowledge of the prevalent drugs in New Zealand helps 
predicting and targeting the possible intoxicants used in 
association with driving. For example, marijuana is the most 
used drug in the country after alcohol and tobacco [11]. Other 
used drugs are opioids, and stimulants like methamphetamine 
[11]. It is also important to take into account the use of 
prescribed medicines in this issue. 
 
Whether these drugs have a real impairment effect or not is 
difficult to prove considering the multiple and complex factors 
involved in their pharmacokinetic and pharmacological stages 
including the phenomenal development of tolerance for regular 
users (especially those under therapy). Many attempts to 
simulate actual “driving under the influence” conditions in 
laboratories, driving simulators and controlled driving areas 
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studies are generally unrealistic because of the legal and ethical 
issues that limit for example the doses taken by volunteers and 
fail to include unpredicted situations that might arise during real 
circumstances. However, results of these studies [12,13] have 
given important information in the elucidation of such 
impairment. 
 
The present work is an epidemiological study, part of the 
project: “Drinking and drugged driver control: delineating the 
problem” that was founded by The New Zealand Police and 
supported by The Institute of Environmental Science & Research 
Ltd. (ESR), The Ministry of Justice, Ministry of Research Science 
and Technology (MORST), Ministry of Health, Alcohol Advisory 
Council of New Zealand (ALAC), Accident Compensation 
Corporation (ACC), LTSA, Ministry of Youth development (MYD), 
Te Puni Kokiri (TPK) and The Ministry of Pacific Island Affairs 
(MPIA), in an attempt to extend the current knowledge about 
drivers under the effect of drugs and alcohol. The general aim of 
this project is to inform the police, thus enabling the 
development and implementation of new strategies that will 
result in a reduction of the road toll. 
 
This research is intended to collect evidence and information that 
lead to a better understanding of the prevalence of drug use and 
the combination of drugs and alcohol and the role cannabis has 
on driving skills and consequently on car crashes. 
 
For the purposes of this thesis, the term car accident or just 
accident will be understood to be a synonym of car crash. 
 
The research part of this work was carried out in ESR (Kenepuru 
Science Centre -Porirua) and consisted of two studies:  
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 Study 1 : evaluates the proportion of drinking drivers 
that test positive for drugs other than alcohol (blood 
samples taken from road side tests).   
 
 study 2 : evaluates the proportion of drivers that have 
died in a car accident and have used drugs and the 
combination drugs-alcohol (blood samples taken from 
coroner cases).  
 
A culpability analysis is intended to discover the role, the most 
prevalent drug used by drivers (marijuana), plays in the accident 
and will be complementary to study 2. This analysis was based 
on the responsibility test methodology designed in Australia by 
Drummer [14-16].  
 
The methodology takes into account the possible factors 
contributing to car accidents such as the condition of the road 
and vehicle. In order to determine the weight these factors have 
in the responsibility, a scoring procedure is used; if the factors 
helped to mitigate the driver’s responsibility in the crash, they 
become causative, if on the contrary, they were not relevant in 
the accident, the driver’s responsibility takes more weight. 
An assessment of the influence of drugs in such responsibility is 
possible after the inclusion of the toxicological results in the 
analysis.  
 
To date (one year data) the number of cases that has passed the 
inclusion criteria (drivers only, road accidents only) is 229. This 
figure allows for an approach to such culpability analysis. 
However, study 2 will be extended until 2000 samples are 
collected and a more solid conclusion on whether cannabis has 
an effect on driving skills or not, is possible. 
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Samples for studies 1 and 2 were collected nationwide. The 
information related to each case was compiled using the police 
traffic crash report form (Appendix 1), in order to include all 
factors judged relevant and contributing to car accidents. 
 
The analytical methodologies followed were previously 
standardized and validated for the extraction of basic drugs, 
benzodiazepines, opioids, cannabinoids and amphetamines by 
the Institute. The analytical techniques employed are: 
 
 Immunoassay, ELISA specifically (for screening analysis) 
 Gas chromatography with nitrogen-phosphorus, mass 
spectrometry and electron capture detection systems (for 
screening and general confirmatory analysis)  
 Liquid chromatography mass-mass spectrometry 
detection (for the specific confirmation of cannabis). 
 
Two thousand blood samples were tested for study 1 with 
collaboration of staff from the Toxicology Laboratory. In study 2, 
240 blood samples from coroner cases were analysed, also with 
assistance of the cited staff, but only 236 included for the 
culpability analysis. The results of these studies were statistically 
analysed under the guidance of a biostatistician from ESR 
(Auckland). A general description is presented in this work. 
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2. Literature Review 
 
 
 
 
2.1 Legislation 
 
There are two approaches to addressing the problem of alcohol 
and drug use while driving; the impairment and per se 
approaches [1,2]. Table 1 describes these different approaches. 
 
 
Table 1. Description of the possible approaches to the 
legislation on alcohol and drugs and driving [1,2] 
 
Approach Description Advantages Disadvantages 
Impairment 
Based on Driver 
performance as 
determined by 
field impairment 
tests. 
The concentration 
of drugs in blood is 
irrelevant in this 
case. 
It was the first 
legislation applied 
to alcohol use. 
 
 No research on 
the effects of 
individual drugs 
is necessary as 
it applies for 
general drug 
use 
 
 Blood or urine 
analysis only 
confirms the 
presence of 
drugs and 
provides a 
possible 
explanation for 
the impairment. 
 
 Legally, this 
approach does 
not obstruct 
constitutional 
rights. 
 
 
 Convictions can 
become difficult 
since the 
assessment of 
impairment 
depends on the 
ability of Police 
officers and/or 
doctors to identify 
impaired drivers 
(subjective 
determination of 
impairment even 
though criteria are 
used). 
 
 Development of 
tolerance in drivers 
becomes a problem 
(drivers might not 
look impaired but 
their driving 
performance might 
be affected). 
 
 Hospitalised drivers 
can not be tested 
for impairment  
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Table 1 continued 
Approach Description Advantages Disadvantages 
Per se 
 
 
An offence is 
committed if drugs 
are detected above 
the legal limit. 
Driving performance 
is irrelevant in this 
case. 
 
In the case of the 
zero-limit approach, 
chosen by countries 
that do not believe 
that drug 
concentrations 
reflect impairment 
(as for alcohol), just 
the presence of 
substances is 
enough for a 
conviction to be 
entered. There is no 
legal limit. 
 
  
 Concentrations 
of alcohol 
and/or drugs 
are easier to 
prove than 
impairment and 
therefore, 
convictions are 
easier to bring. 
 
 Its execution is 
easy and it is 
simple to apply. 
 
 Under zero-limit 
legislation, the 
driver is 
encouraged to 
avoid drug use 
prior to driving. 
 
 
 Concentration limits  
(as for alcohol) do 
not relate to 
individual 
impairment levels.  
Analytical cut-offs 
are usually set. 
 
 For zero-limit 
approaches, a 
scientific proof of 
the deleterious 
effects of drugs on 
driving skills, even 
at small 
concentrations 
might be needed. 
 
 Generally 
concentration limits 
are imposed for 
only a small 
number of (illicit) 
drugs.   
 
 
There are two possible ways to execute these regulations: under 
the administrative or the criminal (prosecution by the order of 
courts) laws [1]. 
 
 
2.1.1 International legislation  
Table 2 lists details of the laws adopted by some European 
countries (from the European Monitoring Centre for Drugs and 
Drugs addiction) [2],  Table 3 lists the legal blood alcohol limits 
for various countries (from the World Health Organization). 
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Table 2. Driving Under the Influence of Drugs 
Legislation in Europe [2] 
 
Country Approach Execution of 
law 
Fine 
 C  
Prison 
(days) 
License 
withdrawal 
(months) 
Austria Impairment Administrative 581-3633  1 
Belgium Per se 
Impairment 
Criminal 
Criminal 
1000-
10000 
15-180 Possible 
Finland Per se 
Impairment 
Criminal 
Criminal 
fine 
60 days 
fine 
182 
700 
Max. 60 
France Per se Criminal 4500 730 36 
Germany Per se 
Impairment 
Administrative 
Criminal 
250 
fine 
365-
1825 
1 
1-3 
Ireland Impairment Criminal 1270 180 24 
Italy Impairment Criminal 260-1030 30 0.5-3 
Netherlands Impairment Criminal 
Injur. 
11250 
Fatal 450 
1095-
3285 
60 
Norway Impairment Criminal  365 12 
Portugal Impairment Criminal 360-1800 365 2-24 
Spain Per se 
Impairment 
Administrative 
Criminal 
302-602 
8-12we 
arrests 
3 
12-48 
Sweden Per se Criminal Day fines 730 1-36 
United 
Kingdom 
Impairment Criminal 7000 180 12 
 
 
 
Table 3. Legal blood alcohol limits set in different 
countries [3] 
 
Country Driver 
BAC limit 
(mg /100mL) 
Vehicle 50 
Commercial vehicle 50 Austria 
Novice 10 
Belgium Any 50 
France Vehicle 50 
Germany Vehicle 50 
Italy Vehicle 50 
Argentina Vehicle 50 
Brazil Any 60 
Chile Vehicle 50 
Oman Any Totally forbidden 
Qatar Any Totally forbidden 
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Table 3 continued 
Country Driver 
BAC limit 
(mg/100 mL) 
United Arab 
Emirates 
Any Totally forbidden 
Vehicle 80 
Malaysia 
Commercial vehicle 80 
Thailand Vehicle 50 
 
 
2.1.2 Legislation in New Zealand 
Presently, there is no specific legislation for the use of individual 
drugs (other than alcohol) and driving in this country. 
 
The current legislation on this matter textually states [4]: 
 
 “A person commits an offence if the person drives or 
attempts to drive a motor vehicle on a road while under 
the influence of drink or a drug, or both, to such an 
extent as to be incapable of having proper control of the 
vehicle.” 
 “If a person is convicted of a first or second offence against 
subsection 1 (previous point), the maximum penalty is 
imprisonment for a term not exceeding 3 months or a fine 
not exceeding $4,500; and the court must order the 
person to be disqualified from holding or obtaining a driver 
licence for 6 months or more.” 
 “If a person commits a third or subsequent offence against 
subsection 1… the person commits an indictable offence 
and on conviction. The maximum penalty is imprisonment 
for a term not exceeding 2 years or a fine not exceeding 
$6,000; and the court must order the person to be 
disqualified from holding or obtaining a driver licence for 
more than 1 year.” 
 12
  “A person commits an indictable offence if the person is in 
charge of a motor vehicle … and causes bodily injury to or 
the death of a person while the person in charge is under 
the influence of drink or a drug, or both, to such an 
extent as to be incapable of having proper control of the 
vehicle… The maximum penalty is imprisonment for a term 
not exceeding 5 years or a fine not exceeding $20,000; 
and the court must order the person to be disqualified from 
holding or obtaining a driver licence for 1 year or more in 
the case of a first or second offence.” 
 “A person may not drive or attempt to drive a motor 
vehicle … while the proportion of alcohol in the person's 
breath, as ascertained by an evidential breath test … 
exceeds 400 micrograms of alcohol per litre of 
breath; or the proportion of alcohol in the person's blood, 
as ascertained from an analysis of a blood specimen… 
exceeds 80 milligrams of alcohol per 100 millilitres of 
blood; or If the person is younger than 20, the proportion 
of alcohol in the person's breath, as ascertained by an 
evidential breath test… exceeds 150 micrograms of 
alcohol per litre of breath; or the proportion of alcohol 
in the person's blood, as ascertained from an analysis of a 
blood specimen… exceeds 30 milligrams of alcohol per 
100 millilitres of blood.” 
 
 
Some of the most important and relevant traffic legislation, 
enacted in New Zealand is shown in Table 4. 
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Table 4. Relevant Legislation on drugs and driving in 
New Zealand [5] 
 
Year Legislation 
1969 Introduction of breath and blood alcohol tests 
1978 
 Introduction of evidential breath testing  
 Lowering of permissible blood alcohol level from 100 mg/100 mL 
blood to 80 mg/100 mL blood. 
1988 
 Lowering the legal breath alcohol level from 500 μg/L to 400 
μg/L 
 Removal of the officers’ right to require a blood sample in 
certain circumstances.  
1989 
Traffic enforcement officers given power of entry onto private 
property for the purposes of undertaking drink driving procedures 
1993 Compulsory breath testing commenced April 1993 
1999 
Roadside license suspension for driving with a blood alcohol level 
above 160 mg/ 100 mL or a breath alcohol level above 800 μg/L or 
for refusing a blood test. 
2001 
 The Land Transport amendment Act 2001 removed legal 
impediments to the operation of breath devices 
 Under the Act, no matter the result of a breath test, a driver has 
the right to request a blood sample (previously limited to drivers 
with alcohol levels of 600 μg/L or below). 
 
 
 
2.2 Drug Use 
 
Information on the prevalence of drugs in different sectors of the 
population can be collected through the use of different 
methodologies. Data collection might involve surveys 
(questionnaires or interviews) applied to the general population 
or subsets of the population. 
 
2.2.1 International 
Efforts from countries worldwide have lead to a better 
understanding of their drug situation in terms of prevalence.  
The United Nations, reported in 2004 some statistics related to 
drug use in different countries [6]. A summary of a selection of 
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these is shown in Table 5, giving the percentage of the 
population between 15 and 64 years old using these drugs. 
 
 
Table 5. Summary of the statistics on The World Drug 
Report 2004 [6] 
 
Drug Region Country Percentage*
Russian Federation 
(2001) 
2.1 
Estonia (2001) 1.2 
Czech Republic 
(2001) 
0.5 
Eastern 
Europe 
Bulgaria (2001) 0.5 
Luxemburg (2000) 1.0 
United Kingdom 
(2000) 
0.7 
Spain (1999) 0.5 
France (1999) 0.4 
Belgium (1997) 0.4 
Western 
Europe 
Germany (2000) 0.3 
New Zealand (2001) 0.7 
Opiates 
Oceania 
Australia (2001) 0.6 
Russian Federation 
(1999) 
3.9 
Estonia (1998) 2.0 
Czech Republic 
(2002) 
10.9 
Eastern 
Europe 
Bulgaria (2001) 1.2 
United Kingdom 
(2003) 
10.6 
Spain (2001) 9.7 
France (2002) 9.8 
Belgium (2001) 6.1 
Western 
Europe 
Germany (2000) 6.0 
Papua New Guinea 
(1995) 
29.5 
Australia (2001) 15.0 
New Zealand (2001) 13.4 
Cannabis 
Oceania 
Fiji (1996) 0.2 
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Table 5 continued 
Drug Region Country Percentage*
Thailand (2001) 5.6 
Philippines (2000) 2.8 
China (2001)* 1.2 
East and 
south Asia 
Japan (2001) 0.3 
Australia (2001) 4.0 
Amphetamines 
Oceania New Zealand 
(2001) 
3.4 
Canada (18+ years 
old) (2002) 
1.8 
North 
America USA (12+ years old) 
(2002) 
1.3 
Colombia (2001) 0.3 
Chile (2002) 0.1 
South 
America 
Venezuela (2002) 0.1 
Australia (2001) 3.4 
Ecstasy 
Oceania New Zealand 
(2001) 
2.2 
       * Taiwan province 
 
Other organisations and programs such as the Global Road 
Safety Partnership (GRSP), The Transport Research Laboratory 
(TRL Limited) in the United Kingdom, The ROSITA (RoadSide 
Testing Assessment) project organised by the European Union, 
The European Observatory of Drugs and Toxicomany, among 
others, are also involved in collecting, analysing and presenting 
data in relation to this issue. 
 
Results of studies on drug use in relation to the driving 
population in some European countries, developing countries, 
Australia and Canada are as follows: 
 
 The prevalence of illicit drugs in Europe in the general 
driving population is 1-5% and in drivers involved in 
collisions is 10-25%. The prevalence of licit drugs in the 
first group is higher, 5-15%, than illicit drug use and licit 
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drug use in drivers involved in collisions is reported as 6-
21% [1,7]. 
 
 Two hundred and ninety three drivers stopped on the road 
in The Netherlands (1997-1998), showed an incidence of 
alcohol use of 12.3%. Cannabis was present in 5.1% of the 
drivers, amphetamines and opiates in the same proportion 
(1.4%) and cocaine in 0.68% [1]. 
 
 In Belgium, 2053 samples collected from injured or 
deceased drivers from 1995 to 1996, showed a high 
occurrence of alcohol (27%), followed by benzodiazepines 
(8.5%), opiates (7.5%), cannabinoids (6.0%) and 
amphetamines (3.0%) [1]. 
 
 A study of 9772 drivers involved in fatal crashes in France, 
revealed 2096 positive cases for alcohol use (21.4%), 681 
positive cases for cannabis in a concentration higher or 
equal to 1 ng/mL (7.0%) and 285 positive cases for the 
combination alcohol-cannabis (2.9%) [8]. 
 
 In Norway (1994), 2529 blood samples from drivers 
suspected of driving under the influence of drugs were 
tested for drugs. Of these, 59% were positive for drugs 
use with 30% alcohol only. The most prevalent drugs were 
benzodiazepines (30.6%), cannabinoids (26.1%) and 
amphetamines (21.1%) [2]. 
 
 Prevalence of drugs in 3398 fatally injured drivers in 
Australia (Victoria, Western Australia and New South 
Wales) was studied overa period of nine years (1990-
1999). Important findings were: 26.7% positive cases for 
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drug use (other than alcohol), 13.5% of which correspond 
to cannabis, 4.9% to opioids, 4.1% equally to stimulants 
and benzodiazepines [9].  
 
 Roadside surveys conducted in Quebec in 1999 and 2000 
indicated that 11.8% of the urine samples taken had drugs 
other then alcohol. The most prevalent drug was cannabis 
(6.7%), followed by benzodiazepines (3.6%), opiates 
(1.2%) and cocaine (1.1%) [7]. 
 
 Very few studies on drugs and driving have been carried 
out in Africa, however a roadside survey conducted in 
Kenya (1997), in which 479 drivers were tested for alcohol 
by breath devices showed 19.9% of the cases as being 
positive for alcohol (8.3% > 0.5g/L and 4% > 0.8 g/L); all 
drunk drivers were male older than 25 years old [10]. 
 
 Likewise, there is not much information on the drugs and 
driving situation in South America. Colombia reported 34% 
of fatally injured drivers had used alcohol. In Argentina, 
83% of drivers surveyed self-reported that they drove 
under the influence of alcohol [10]. 
 
2.2.2 In New Zealand 
A chronological account of studies conducted in New Zealand, 
reflecting different aspects of the drugs situation in the country 
is presented below. Table 5 also shows some comparative 
statistics of drug use in New Zealand in relation to other 
countries in the world.  
 
The first study performed in this country intending to analyse the 
role of drugs (other than alcohol) in car accidents, was the 
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Waikato Hospital Road Accident Survey (1979/80) [11]. Some 
results of this survey are: 
 
 Of the 822 injured drivers tested for cannabis, 7.2% were 
positive for it (radioimmunoassay). However there was no 
proof of impairment by cannabis at the moment of the 
accidents. Confirmation techniques were not carried out. 
 
 Only one driver of the 901 included in the survey was said 
to be impaired with a prescription drug (single use). In two 
other drivers, the prescribed drugs might have increased 
the adverse effects of alcohol. 
 
 17% of the drivers tested positive for alcohol at a 
concentration higher than 80 mg/100mL. 
 
A research paper published in 1995 about alcohol and fatal road 
crashes that occurred between 1991 and 1993 [12], used data 
sources including ESR’s post-mortem and blood alcohol data, and 
Coroners’ reports.  Important findings are as follows: 
 
 Of the total number of cases studied, 450 were positive for 
alcohol and 757 negative. 
 
 60% of the drivers (positive for alcohol) had blood alcohol 
levels higher than 150 mg/ 100 mL. 
 
 Fatal accidents involving alcohol occurred more often from 
9.00 pm to 5.00 am. 
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The role of cannabis in fatal road accidents was studied in a 
sample of 386 fatally injured drivers, over a two year period  
[13].  Important results and conclusions were reached: 
 
 41% of the drivers were positive for alcohol and 21% for 
THC. 
 
 About 67% of the drivers who tested positive for cannabis 
also had alcohol in blood. This combination was more 
prevalent than cannabis use alone. 
 
 There seems to be a clear relationship between cannabis 
use and excessive use of alcohol. The blood levels of 
alcohol found in drivers who used the combination of drugs 
were on average higher than the levels of drivers who used 
alcohol alone. Therefore, a pattern of social behaviour can 
be suggested. 
 
An article published by the New Zealand Medical Journal in 1998 
[14], mentions some anecdotal and research evidence related to 
the cultivation and production of cannabis. The climate and 
geographic conditions of this country have permitted the easy 
cultivation of the marijuana plant to the point that the 
importations are minimal.  It is also said that in-house 
hydroponic cultivations are camouflaged in legal businesses, and 
the supply of cannabis became a means of economical 
subsistence for some Maori communities living in rural areas. 
 
Several birth cohorts have been studied in New Zealand [15]. 
One of the most recent ones, aimed at linking cannabis use and 
risk of car accidents [16], gathered data from 907 young New 
Zealanders (born in Christchurch) aged 21 who had driven 
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vehicles since age 18. A statistically significant association 
between reported car accidents and cannabis use was found. The 
risk rate was 1.6 times higher for cannabis users than for non-
users, the risk was related to the behavioural characteristics of 
young cannabis users rather than impairment due to cannabis 
use itself.   
 
The New Zealand drug statistics published in 2001, collected 
data from surveys and event-based statistics (like hospital 
records of drug use). The report showed alcohol as the most 
used recreational drug in the country followed by tobacco and 
cannabis [17]. 
 
The most recent statistics on this topic were reported in the 
2002/03 New Zealand Health Survey [18]: 
 
 83.5% of the people surveyed had drunk an alcoholic 
beverage in the preceding 12 months.  
 
 19.1% of the people aged 15 years old or more had a 
drinking pattern that represented risk of physical or mental 
damage in the future (hazardous drinking). Of these, 
27.1% were men and 11.7% women. 
 
 One in seven adults surveyed, admitted having use 
marijuana (smoked) the year previous to the survey. 1 in 
19 smoked it on a regular basis. 
 
In 2004, 12% of injury crashes and 30% of fatal crashes 
involved alcohol and/or drug use [5].  
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2.3 Studies 
 
The worldwide problem of drugs use has lead to governments 
developing laws that attempt to reduce the incidence of drug-
related road crashes. These laws are most of the time based on 
studies that reveal the prevalence and effects of legal and illegal 
drugs, and their combinations, and the responsibility of these 
drugs in road crashes. 
There are two possible situations in which the studies can be 
conducted: In the field (epidemiological studies involving 
culpability analysis, prevalence of drugs in crashes, case-control 
studies) and in the laboratory (experimental studies involving 
driving simulators, on-the-road driving tests and psychomotor 
tests) [19,20]. 
 
The approaches used by researchers who aim to establish a 
possible relationship (in terms of responsibility) between 
cannabis or other psychoactive drugs and the risk of motor 
vehicle accidents, are reviewed below. 
 
 
2.3.1 Driving simulator and On-the-road studies 
approach 
Analysis of the skills necessary for a good standard of driving 
performance (vigilance, perception of speed and risks, etc.) can 
be executed through psychomotor tests, the use of a simulator 
or real driving studies [21].   
 
In the case of the simulator, the computer generates a setting 
imitating real driving conditions with the possibility for 
researchers to include sudden situations or obstacles [21]. A 
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problem associated with this kind of test is the lack of realism 
present in actual driving circumstances [20].  
Some irregularities have been reported when analysing cannabis 
use in driving simulators: increase of the lateral position 
variability, as well as reaction time, decision taking, and traffic 
signs and navigational information are ignored [20,21]. 
However, manifestations that partially compensate for the 
impairment have also been observed: a longer distance is 
maintained when following cars and a general tendency to drive 
slowly [20].  
 
On-the-road studies can be performed on closed circuits or 
controlled driving on public roads. Problems related to this kind 
of study are generally ethical; the quantities of cannabis (or 
other drugs of interest) given to the participants are controlled 
and might not represent real use cases. The average dose to get 
a “high” with this drug oscillates in the order of 300 μg/Kg 
[20,21]. 
 
Researches have shown that severe driving impairment was 
present when cannabis was combined with low doses of alcohol 
(BAC < 50 mg / 100 mL) in “road tracking tests”, “car following” 
and “city driving” tests [20]. 
 
2.3.2 Case-control study approach 
Case-control studies are epidemiological studies that tend to 
involve a demonstrative and comparable control group [20], that 
will match the case group (injured or fatally injured drivers) in 
terms of time and location (same place, same day of the week, 
hour, etc, weeks after the accident) [22]. 
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A problem found with this kind of study (at least for cannabis 
analysis) is the lack of devices for the easy identification of drugs 
at the roadside. Ethical issues associated with the sample (blood) 
collection arise for the control group [22]. 
 
A good example would be a prospective case-control study 
performed in The Netherlands (May 2000 – August 2001), 
intended to evaluate the association between the use of 
psychoactive drugs and car crashes where hospitalisation was 
required [23]. Details and results (statistically significant) of this 
study are presented below. 
 
 The case group was car or van drivers involved in a vehicle 
accident, from whom blood and/or urine samples were 
taken at the hospital. 
 
 The control group was drivers randomly chosen from public 
roads at different times of the day and days of the week 
and who voluntarily gave a urine or blood sample and 
responded to an interview. 
 
 The risk for car accidents after single use of 
benzodiazepines was 5.1 times higher than for the control 
group. In the case of alcohol the odds ratio was O.R: 5.5 
(BAC= 50-79 mg/100 mL) and O.R: 15.5 (BAC ≥ 80 
mg/100 mL). 
 
 Cases when a combination of drugs (other than alcohol) 
were involved, gave a high odds ratio of 6.1. Drivers who 
used a combination of alcohol and other drugs had an 
extremely high odds ratio of 112.2. 
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 No increased risk of car accidents was found for drivers 
who used cannabis. 
 
2.3.3 Culpability or Responsibility study approach 
Culpability studies are epidemiological studies, that can be 
considered as case-case studies (both groups have been involved 
in motor vehicle crashes) [22]. After evaluation of the 
responsibility for the drivers on the accident (without prior 
knowledge of the involvement of drugs), the not culpable group 
is assigned as the equivalent to the control group (for 
calculations). The odds ratio of drivers with no evidence of drug 
use is assumed 1.0 [20]. 
 
Problems related to this approach arise from the lack of 
statistical power associated to the size of the sample under study 
[20]. 
 
Drummer et al carried out an important 10-year responsibility 
study in three Australian states [9]. Details and results of this 
study are shown below. 
 
 All possible factors that might contribute to car accidents 
were taken into account for culpability scoring purposes. 
Drivers were divided into three groups, depending on the 
culpability score: culpable, contributory and non-culpable 
(a more detailed description of the methodology used can 
be found in Chapter 4, Study 2).  Statistically significant 
interactions were analysed by using a logistic regression 
model. 
 
 Of the 3398 fatally injured drivers, 1704 were drugs-free  
(control group) and 1694 were positive for drugs (case 
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group). Of the control group, 1214 drivers were culpable of 
the accident and 376 were not culpable (114 contributory), 
likewise, 1487 drivers from the case group were culpable 
and 133 not culpable (74 contributory). 
 
 Cannabis use was found to be associated with culpability. 
The risk of having a car accident after using cannabis was 
2.7 times higher than for the control group. 
 
 Results also suggested that cannabis enhanced the 
impairment caused by alcohol. The culpability odds of 
drivers with THC and alcohol (≥ 50 mg/100 mL) was 2.9 
times the odds of drivers who had the same alcohol levels 
alone. 
 
 
2.4 Drugs 
A summary of the most relevant effects, exhibited by the drugs 
of interest for this work (alcohol, cannabis, amphetamines, 
benzodiazepines and opiates), is presented in Table 6. 
 
 
Table 6. Uses and effects of the drugs considered in the 
thesis 
 
Ref. Drug 
Drug  
class 
Uses 
General 
effects 
Effects on 
driving 
[19, 
24,25] 
Alcohol 
(alc.)  
CNS 
depressant 
Currently, 
alcohol is 
used in 
social 
occasions   
 
At low 
concentrations 
alc. helps 
people to lose 
some 
inhibitions. 
 
↓  Intellectual 
performance, 
speed and 
accuracy of 
reaction to 
visual and 
auditory stimuli. 
 
Alters 
concentration, 
reaction time, 
tracking. 
 
↑ risk taking 
behaviour, 
impulsiveness. 
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Table 6 continued 
 
Ref. Drug 
Drug  
class 
Uses 
General 
effects 
Effects on 
driving 
[19, 
24,25] 
Alcohol 
(alc.)  
CNS 
depressant 
For example in 
parties, 
reunions, etc. 
 
Typically, 
interactions 
occur with other 
CNS 
depressants. 
 
↑ risk of 
having a car 
accident and 
the 
responsibility 
for it. 
[26] Cannabis 
Because of its 
unique 
pattern of 
effects, 
classification 
of this drug as 
either 
sedative, 
stimulant or 
hallucinogen 
is difficult 
Used medically 
for the 
treatment of 
anorexia in 
patients with 
AIDS and for 
the treatment 
of nausea and 
vomiting 
related to 
cancer therapy 
 
Effects depend 
on the dose, the 
administration 
route, the 
experience of 
the user, 
between others. 
 
General effects 
include: 
euphoria, 
relaxation, sense 
of well being, 
lack of 
expression, 
altered memory 
and learning, 
sedation, panic, 
and paranoia. 
 
↑ reaction 
time. 
 
Alters 
estimation of 
distance, 
speed 
variability. 
 
Inability to 
keep lateral 
position. 
 
Motor 
incoordination 
and impaired 
vigilance. 
 
Impaired 
steering, 
decision 
making and 
concentration.  
[26] 
 
 
Morphine 
 
Narcotic 
analgesic 
 
It is clinically 
used for the 
treatment of 
pain 
(moderate to 
severe) 
It is also used 
as sedative 
before surgery 
helping with 
the induction 
of anesthesia  
 
The effects are 
closely related to 
the dose, 
administration 
route and prior 
experience. 
 
Typical physical 
effects are: dry 
mouth, heavy 
extremities. 
 
Euphoria, 
relaxation, 
sedation, 
delirium and  a 
sensation of 
well-being, are 
examples of 
psychological 
effects. 
 
Affects motor 
reactions, 
vigilance and 
concentration 
 
↑ reaction 
time 
 
Slow driving, 
deficient 
vehicle 
control, 
weaving, late 
reactions, bad 
coordination 
and slow 
response to 
stimuli. 
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Table 6 continued 
 
Ref. Drug 
Drug  
class 
Uses 
General 
effects 
Effects on 
driving 
[26] 
Metham-
phetamine 
(MA) 
CNS 
stimulant 
 
Medicinal 
uses include 
the 
treatment of 
narcolepsy, 
ADHD 
(Attention 
Deficit 
Hyperactivity 
Disorder and 
ADD 
(Attention 
Deficit 
Disorder) 
 
Two phases 
can be 
identified 
after the use 
of MA.  
1st stage 
involves 
euphoria, 
fast-talking, 
hallucinations, 
↓ fatigue, ↑  
attentiveness. 
 
2nd stage 
involves 
dysphoria, 
restlessness, 
violence, 
aggression 
and 
psychosis. 
 
Failure to stop, 
impatience, 
speeding, risky 
driving 
behaviour, 
erratic driving. 
 
Due to 
distraction, 
hyperactive 
reflexes, 
disorientation 
and motor 
excitation, 
between 
others. 
[26] MDMA 
Mild CNS 
depressant, 
hallucinogen 
and 
psychedelic 
Currently 
there are no 
legal medical 
uses for 
MDMA in 
several 
countries.  
Originally 
was used as  
appetite 
suppressant. 
 
Relaxation, 
euphoria, 
well-being 
sensation. 
 
Affects 
perception 
and empathy. 
 
↑ response to 
tactile stimuli. 
 
Higher doses  
produce panic 
attacks, 
hallucinations 
and agitation. 
 
Speeding, 
failure to 
respect traffic 
lights. 
 
Effects in 
vehicle control. 
 
Impaired 
tracking ability, 
slow reactions 
[24, 
26] 
Benzo-
diazepines 
(BD) 
e.g 
diazepam 
Tranquilizers, 
sedatives, 
CNS 
depressants 
 
Treatment of 
insomnia 
and anxiety, 
epilepsy, 
convulsive 
disorders  
 
Sedation, 
poor 
coordination, 
drunken-like 
state. 
 
Can induce 
disinhibition. 
 
↓ alertness 
 
impairs 
perception of 
time, space 
and distance 
  
 
It seems that 
not all BD  
produce 
impairment. 
Some studies 
did not find 
differences 
between BD 
positive and 
negative 
drivers [19]. 
 
↑ lateral 
deviation 
 
↓ multitasking  
and attention 
  Conventions: ↑ increases,  ↓ decreases. 
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3. Study 1 
 
 
Study 1 is intended to determine the proportion of drinking 
drivers that test positive for drugs other than alcohol. 
 
Under the current legislation for drink-driving in New Zealand, 
drivers are asked to undertake alcohol breath tests (passive 
breath test, breath screening test and evidential breath test). 
These tests are performed through different devices that screen 
and confirm the presence of alcohol and the concentrations; 
evidential breath test results are used in court as evidence.  
 
Drivers also have the option to submit a blood sample for testing 
or not. Blood tests are conclusive proof of alcohol intake in levels 
exceeding the legal limits3 [1]. Therefore, not all drivers found to 
have high levels of alcohol (compared to the limits) submit a 
blood sample. 
 
 
3.1 Materials 
 
3.1.1 Population 
The population studied was drivers stopped for roadside 
screening of alcohol who had breath alcohol concentrations 
above the legal limit and provided evidential blood alcohol 
samples. This population does not completely represent the 
general driving cluster (approx. 2,997,494 licensed drivers4 [2]) 
but the uninjured drink driving population who were 
apprehended and provided a blood sample. 
                                                 
3 “ No matter what the result of a breath test, a driver has the right to request a blood sample”. 
The Land Transport Amendment Act, 2001 [1]. 
4  Current and limited licence holders (30/04/2006) not including drivers with international 
licenses [2]. 
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In the fiscal year 2004-2005, there were approximately 26,036 
positive cases of breath screening tests and 26,519 charges for 
alcohol offences [3]. 
 
3.1.2 Samples 
A set of 2000 blood samples was randomly selected from the 
pool of roadside samples taken by the police in a time period of 
about 1 year. 
 
Acceptance criteria for the inclusion of samples in this study are: 
 
 Circumstances: drivers (uninjured) who gave positive test 
results and opted for a blood test. 
 
 
3.2 Methodology 
 
3.2.1 Analytical methodology 
The blood samples were screened for the possible presence of 
drugs. The screening technique used was ELISA, where the 
analyte in the sample, competes with the enzyme labeled 
antigen (drug derivative) for a limited and constant number of 
antibody units attached to the polystyrene micro-plates. The 
colour that develops after the addition of the chromogenic 
substrate is monitored at 450 nm.  
 
This screening method has been widely used in forensic science 
and other sciences since the 1970s [4]. It is consider sensitive, 
very simple and useful in terms of cost-effectivity [5,6]. Cross-
reactivity, although an issue in immunoassays, does not prevent 
their broaden use, as long as it is determined and known. 
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The alcohol concentration was determined in duplicate by an ESR 
staff member using GC-FID headspace chromatography.  
 
Table 7 lists the drug tests performed and relevant parameters 
of the kits according to the manufacturer [7-10]. The cut-off 
standard used in the laboratory is also included in this Table. The 
reagents, equipment and methodology used are shown in detail 
in Appendices 2 and 3. 
 
In this study, only preliminary test results (positive or negative) 
were used to give an idea of the incidence of drugs within the 
drink-driver population. No confirmatory techniques were 
involved since only group of drugs were target (confirmatory 
techniques are used to verify the presence of specific drugs 
and/or metabolites). 
 
 
 
Table 7. Drugs screened in study 1 and performance 
parameters of the ELISA kits 
 
Drugs Accuracy*
Precision 
c.v. 
Sensitivity**
Cut-off 
level 
d-methamphe-
tamine 
100%  
(50 ng/mL 
cutt-off) 
MA 
5.4% 
(o ng/mL) 
 
12.2% 
(25 ng/mL) 
1 ng/mL of 
methamphe- 
tamine 
MA 
25 ng/mL 
morphine 
100% 
(25 ng/mL 
cutt-off) 
morphine 
9.5% 
(0 ng/mL) 
 
12.83% 
(25 ng/mL) 
1 ng/mL of 
morphine 
morphine 
20 ng/mL 
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Table 7 continued 
 
Drugs Accuracy*
Precision 
c.v. 
Sensitivity**
Cut-off 
level 
Benzodiazepines 
100% 
(50 ng/mL 
cutt-off) 
oxazepam 
5.3%   
(0 ng/mL) 
 
9.1% 
(25 ng/mL) 
2 ng/mL of 
oxazepam 
oxacepam 
1 ng/mL 
cannabis 
100% 
(20 ng/mL 
cutt-off) 
CTHC 
7.3% 
(0 ng/mL) 
 
7.7% 
(10 ng/mL) 
1 ng/mL 
of THCA 
THC 
10 ng/mL 
* Accuracy determined in terms of percentage of positive and negative samples (confirmed by other technique) 
that tested positive and negative respectively by ELISA. 
** Based on the minimum amount to produce a deviation of 4 sd (standard deviations) [9].   
 
 
In terms of specificity of the kits used, cross-reactivity with 
related drugs permitted the determination of the groups of drugs 
targeted: 
 
 D-L-methamphetamine, important cross-reactivity is seen 
with D,L-MDMA.  
 
 For morphine, the kit detects codeine in addition to 
morphine.  
 
 In the group of benzodiazepines, alprazolam, estazolam, 
diazepam, nordiazepam and α-OH alprazolam are 
detected, however, low doses of some benzodiazepines 
might not be detected and so underestimation of the total 
amount of positive cases (for individual and multiple drug 
use) might occur.  
 
 The cannabis kit detects 11-nor-9-carboxy-Δ8-THC, Δ9-THC 
and Δ8-THC. 
 
On the other hand, none unrelated drugs (acetaminophen, 
acetylsalicylic acid, caffeine, ibuprofen and some other drugs of 
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abuse or prescription such as cocaine, methadone) give results 
greater or equal to the sensitivity value.  
 
 
3.2.2 Statistical methodology 
A framework (Figure 1) for the collection of the sample was set 
at the beginning of the study, as the main objective of this part 
of the project was to gather information about the occurrence of 
drivers who in addition to alcohol consumption, use single or 
multiple drugs. 
 
The database provided by the Police, which included basic 
information such as self-reported occupation data (drivers, 
courier drivers, bus drivers etc.), age and gender, was cross-
correlated with the toxicology results from ESR (Table 8) by the 
project statistician to obtain statistical inferences on drug and 
alcohol use within driver categories. The analysis was performed 
using the Statistical Analysis Software System (SAS version 9.1). 
 
The incidence of drugs and alcohol within the driver population 
was then evaluated in terms of age range (15-19, 20-24, 25-34, 
35-44, 45-64, 65+ and unknown), gender (male, female, 
unknown), type of drugs, blood alcohol concentration (≤ 30 
mg/100mL, 31-80 mg/100mL, 81-160 mg/100mL and ≥ 160 
mg/mL) and commercial drivers. The percentage of drivers for 
each category was calculated from the total number of relevant 
cases (Appendix 4). 
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Figure 1. Framework for study 1 
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All the alcohol concentration results were statistically adjusted to 
take into account the uncertainty of the measure, in order to do 
this, six (three standard deviations) are always deducted from 
every concentration determined. This practice is especially 
important when concentrations fall within the legal limits, 
preventing false positives to occur and providing drivers with the 
benefit of the doubt. 
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Table 8. Databases and relevant information 
 
Source Police ESR 
General  Laboratory data 
In
fo
rm
a
ti
o
n
 
name**
age on date sampled 
date of birth 
gender 
driver category*: (bus, 
courier, commercial, taxi, 
truck drivers) 
date sampled 
date reported 
name** 
 ESR ID number** 
ethanol 
methanol*** 
acetone***
isopropanol***
cannabis 
methamphetamine 
morphine 
benzodiazepines 
date sampled 
date reported 
         * Self reported, **Confidential, ***Not used in this work but part of the general project. 
 
 
The ESR database will be destroyed at the end of the study. 
Police will not have access to drug results associated with the 
identification of the drivers 
 
 
3.3 Discussion and Results 
 
General descriptive statistics of the 2000 samples analysed, led 
to important inferences about road users in New Zealand.  The 
results however, are not completely representative of the 
general driving population, represent the uninjured drink driving 
population. 
 
37% (741) of the 2000 cases tested positive for drugs (one or 
more). From these, 95% (705) screened positive for individual 
drug use in addition to alcohol and the remaining 5% (36) had 
multiple drugs in their blood.  
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3.3.1 General findings 
Amongst drivers who had used a single drug (other than 
alcohol), cannabis was by far the most prevalent at 89.2% 
(661/741) of the positive cases. 
 
Important combinations of drugs seen were: cannabis – 
benzodiazepines (2.8%, 21/741) and cannabis – 
methamphetamines (1.6%, 12/741). Multiple drug consumption 
is dangerous, especially when experienced with alcohol. Strong 
adverse effects in terms of driving skills have been reported [11-
16]. A better picture of this problem might be reflected in the 
study of casualties and culpability analysis; Study 2 (Chapter 4).  
 
Out of the 2000 drivers who tested positive for alcohol, 35% 
(696) also had consumed cannabis, 2.9% (58) benzodiazepines, 
1.1% (22) used methamphetamines and 0.15% (3) had used 
morphine or heroin.   
 
Figure 2 and 3 present the data for study 1 in a graphical way 
and the breakdown table summarizes it (Appendix 4). 
 
Despite the common belief that cannabis use is generally not 
combined with alcohol and driving activities, cannabis is the 
most popular non-alcoholic drug found in the drinking driver 
group of people. This is consistent to drug abuse statistics in 
New Zealand [17], international trends [18-20] and the results 
obtained in Study 2. 
 
Compared to cannabis, the sum of all the positive cases for the 
use of the other drugs was small (4%). 
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Figure 2.  Breakdown of results in the general drinking 
driver population 
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Figure 3.   Percentage of drinking drivers with and without 
drugs* 
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3.3.2 Age and gender parameters 
The variables age and gender related to drug and alcohol 
consumption gave important information on tendencies of the 
selected portion of the driver population.  For example it seems 
that there are more male drivers (about six times) using drugs 
as well as alcohol while driving than the equivalent female 
sample.  
 
However consideration must be given to the fact that more male 
drivers (about 5 times) were tested in comparison to the female 
sample4 and that there are about the same amount of male and 
female licensed drivers in the country5 [2] (considering that only 
licensed drivers are allow to drive in New Zealand).  This might 
be due to the fact that blood samples are provided optionally and 
the random nature of the sampling is affected. 
                                                 
4  For different reasons, gender was unknown for 17 drivers 
5  Current and limited licence holders (30/04/2006) not including drivers with international 
licenses [2].  
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Over-representation of the male sample might lead to 
underestimation of the results for the female counterpart (in 
terms of prevalence). In other words, it is more realistic to state 
that drug consumption is, to some extent, more prevalent in the 
male than in the female drink-driving population rather than 
present figures. 
 
Even though there is not an equal number of cases for each age 
range (comparisons between age groups are not really possible), 
some assumptions and conclusions can be made: 
 
Single drug use 
 
 The alcohol limit for drivers under 20 years old is 
30mg/100mL of blood. 48% (116/241) of the drivers in 
the earliest age (15-19 years old) tested positive for 
drugs. A large proportion of drivers consumed cannabis 
(47%, 114/241), of this figure, 83% (95/114) were male 
drivers. There was not multiple drug use in this group. 
 
 A high prevalence of cannabis was found in the group of 
drivers between 20 and 24 years of age (second youngest 
group) and the 25 to 34 group, where 23% (150/161) and 
28% (188/161) of the total positive cases for cannabis 
respectively fell. 92% (138/150) of drivers in the first age 
group were men as well as 86% (162/188) of the second 
group.  
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 The use of methamphetamine or MDMA was evenly spread 
over drivers aged 20-44 (25% of all positive cases for 
every subgroup of age). 
 
 Benzodiazepines were found mainly in the older drivers 
groups. 31% (11/35) and 34% (12/35) of the drivers with 
benzodiazepines at 35-44 and 45-64 years old 
respectively, reflecting possibly that this is the age group 
more commonly prescribed with this kind of drugs 
(legitimate use). It is important also to consider the 
development of tolerance on these drivers. 
 
 
Multiple drug use 
 
 Multiple drug use was more prevalent in the 25-34 and 
the 35-44 years old groups, 6.3% (13/207) and 6% 
(11/166) of the total number of drivers (positive for 
drugs) at each age range. 
 
 Cannabis + methamphetamine combined use was most 
evident in drivers from 25-44 years old and cannabis + 
benzodiazepines use arose mainly in the older population. 
 
The breakdown of the previous results can be seen in Appendix 
4, the general results are summarized in Table 9. 
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Table 9.  Number and percentage of drivers with and 
without drugs by gender and age categories for Study 1 
 
Age groups  (years old) 
Drug 
use 15-19 20-24 25-34 35-44 45-64 65 + UK* Total 
Gender 
97 
(13%) 
146 
(20%) 
179 
(24%) 
141 
(19%) 60 (8%) 
5 
(1%) - 
628 
(85%) Male 
19 (3%) 14 (2%) 28 (4%) 25 (3%) 19 (3%) 1 1 
107 
(14%) female 
- - - - - - 
6 
(1%) 
6 (1%) UK*
Positive 
116 
(16%) 
160 
(22%) 
207 
(28%) 
166 
(22%) 
79 
(11%) 
6 
(1%) 
7 
(1%) 
741 Total 
98 (8%) 
157 
(12%) 
200 
(16%) 
235 
(19%) 
299 
(24%) 
31 
(2%) 
1 
1021 
(81%) Male 
27 (2%) 34 (3%) 59 (5%) 46 (4%) 56 (4%) 4 - 
226 
(18%) Female 
- - - - 1 - 
11 
(1%) 
12 
(1%) UK
*
Negative 
125 
(10%) 
191 
(15%) 
259 
(21%) 
281 
(22%) 
356 
(28%) 
35 
(3%) 
12 
(1%) 
1259 Total 
Total 241 351 466 447 435 41 19 2000 Total 
* Unknown 
 
 
 
 
3.3.3 Alcohol levels 
To analyse the relationship between alcohol concentrations and 
drug consumption, the ranges of alcohol concentration were set 
taking into account the legal limits. Table 10 shows this 
relationship, Appendix 5 shows the breakdown of positive cases 
by age and alcohol concentrations, and Figure 4 presents the 
number of cannabis and alcohol users throughout the different 
age ranges and alcohol levels. Important observations derived 
from these results are as follows: 
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 Drivers at all levels of alcohol consumption, used cannabis. 
The most significant figures (Figure 4) were seen at 81-
160 mg/100 mL (55%, 362/661) and ≥ 161 mg/100mL 
(31%, 203/661). However, it is important to consider that 
the number of drivers tested for each age range was not 
the same, which makes comparisons difficult.  
 
 In the group of 25 to 34 year old drivers, the highest use 
of cannabis was seen in combination with alcohol levels of 
81-160 mg/100mL (23% of the total number of drivers at 
this age range (107/466) and 16% of the total number of 
positive cases at this alcohol level). 
 
 Cannabis use was more prevalent within the male driver 
population at all alcohol levels (86%, 567/661) in 
comparison to the female population (13%, 88/661). Six 
cases fell in the unknown gender category. This fact was 
most evident at the alcohol level of 81-160 mg/100mL 
where 89% (324/362) of the positive results for cannabis 
was found in male drivers. Consideration must be given to 
the different number of individuals tested for each gender 
group. 
 
 Most benzodiazepine use was found at higher levels of 
alcohol, 60% (21/35) of the total number of drivers with 
benzodiazepines at ≥ 161 mg/100mL. Of this, 76% fell in 
the age ranges of 35-44 and 45-64 years old. 
 
 There was no significant difference in the use of 
methamphetamines in relation to age ranges.  
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Table 10.   Number and percentage of drivers with and 
without drugs at different alcohol levels 
 
Alcohol level (mg/100mL blood) Drug use 
(single and 
multiple) ≤ 30 31-80 81-160 ≥ 161 Total 
Positive 
21 
(54%) 
84 
(47%) 
399 
(36%) 
237 
(35%) 741 
Negative 18 
(46%) 
94 
(53%) 
715 
(64%) 
432 
(65%) 1259 
Total 
39 
(2%) 
178 
(9%) 
1114 
(56%) 
669 
(33%) 2000 
 
 
 
Figure 4.    Incidence of cannabis and alcohol use in 
relation to the alcohol levels and age range 
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3.3.4 Driver category / Commercial drivers 
2.6% (52) of the 2000 samples studied were catalogued as 
commercial drivers (information taken from self reported 
occupations). 
 
Two of the 52 commercial drivers were women and neither 
showed evidence of drug use. 23% (12/52) of male drivers were 
found to have used drugs. There were no positive results for 
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methamphetamines or morphine but 11 of the drivers tested 
positive for cannabis. 
The incidence of drugs in the commercial drivers is lower than in 
the general sample of male drivers. 
The number of commercial drivers tested is small and might not 
represent this population adequately. There was no information 
on whether these drivers were working when apprehended. 
 
Table 11 presents the results in terms of the number of 
commercial drivers with and without drugs by age. 
 
Table 11.   Number and percentage of commercial drivers 
with and without drugs by age category 
 
Age (years old) 
General drug use 
15-19 20-24 25-34 35-44 45-64 Total 
Positive - 3 
(25%) 
6 
(50%) 
2 
(17%) 
1 
(8%) 
12 
(23%) 
Negative 1 
(3%) 
3 
(8%) 
6 
(15%) 
10 
(25%) 
20 
(48%) 
40 
(77%) 
Total 1 
(2%) 
6 
(11.5%) 
12 
(23%) 
12 
(23%) 
21 
(40%) 
52 
Individual use  
Cannabis - 3 
(27%) 
6 
(54.5%) 
2 
(18%) 
- 
11 
(92%) 
Benzodiazepines - - - - 1 1 
(8%) 
Total - 3 
(25%) 
6 
(50%) 
2 
(17%) 
1 
(8%) 
 
12 
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4. Study 2 
 
 
Police officers attending serious car crashes are required to 
register details of the circumstances related to the event in a 
standarised form (Police crash report. Appendix 1).    
 
In the case of fatal cases (Coroner cases), a post-mortem 
evaluation is completed by a certified pathologist in order to 
determine if the cause of the death was natural or due to 
external factors (the accident itself for example). 
 
The information conveyed is then used as evidence in court. 
 
Study 2 is intended to determine the proportion of drivers who 
have died in a car accident and have used drugs and/or alcohol.  
 
 
4.1    Materials 
 
4.1.1 Population 
The population studied was deceased drivers involved in single or 
multiple car crashes (Coroner cases).  
 
4.1.2 Samples 
Blood samples from two hundred and forty coronial cases 
collected over a one year period (July 2004 - June 2005) were 
analysed. 
 
Acceptance criteria for the inclusion of samples in the study are: 
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 Specimen: blood (enough volume for drug identification 
and confirmation / quantitation assays). Sometimes, 
depending on the conditions of the body, only small 
volumes of blood are able to be collected. 
 
 Circumstances: drivers, fatal victims of car crashes on the 
road (intercity, inner-city and rural roads). 
 
 
4.2 Methodology 
 
4.2.1 Analytical methodology 
The blood samples taken from drivers, killed in car crashes were 
screened for alcohol, cannabis, methamphetamine, MDMA, 
morphine and commonly prescribed medicinal drugs that may 
affect driving ability. 
 
One of the screening techniques used to determine the general 
presence of drugs was ELISA (as described for Study 1, Appendix 
3). Unlike Study 1 however, ELISA was only used to screen for 
methamphetamines, morphine and cannabinoids. 
Benzodiazepines were analysed by another technique. 
 
All positive drug indications from the ELISA screening technique 
were subsequently submitted to confirmatory analysis to 
conclusively establish the presence or absence of indicated 
drugs.  
 
Liquid-liquid extraction followed by GC-ECD chromatography was 
used for the screening and confirmation of a range of 
benzodiazepines and zopiclone. Liquid-liquid extraction and 
subsequent GC-MS-NPD chromatography was used for the 
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screening and confirmation of basic and neutral medicinal drugs. 
A full description of the methodologies applied is given in 
Appendix 6 and examples of the substances detected in each of 
them are shown in Table 12. The alcohol determination, as for 
Study 1, was carried out by GC-FID headspace. 
 
 
Table 12. Example of drugs detected with the liquid-
liquid screening techniques in Study 2 
 
Technique Drugs 
benzodiazepines 
 
diazepam / 
nordiazepam 
clonazepam 
triazolam 
temazepam  
oxazepam 
nitrazepam 
alprazolam 
Liquid-liquid 
/ GC-ECD 
other drugs 
phenobarbital 
zopiclone 
kavain 
antihistamines 
chlorpheniramine 
diphenhydramine 
promethazine 
pheniramine 
narcotic 
analgesics 
 
 
codeine 
dihydocodeine 
methadone 
tramadol 
dextropropoxyphene 
pethidine 
antidepressants 
amitriptyline 
nortriptyline 
doxepin 
imipramine 
venlafaxine 
 
Liquid-liquid 
/ GC-MS-
NPD 
Basic   
and neutral 
drugs 
other drugs 
ketamine 
olanzapine 
carbamazepine 
chlorpromazine 
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Details of the confirmation and quantitation assays are shown in 
Table 13, the reagents, equipment and the methods used are 
shown in Appendices 2 and 6. 
 
Table 13. Analytical techniques used for the confirmation 
and quantitation assays of study 2 
 
Drug Technique Equipment 
Detection 
limit 
Accuracy 
 
Precision 
interday 
CV (%) 
Methamphe- 
tamine and 
MDMA 
Gas 
chromatography 
GC/MSD 25 ng/mL - 
12.2 (at 25 
ng/mL) 
morphine Gas chromatography GC/MSD < 20 ng/mL - 
< 10 (at 20-
250 ng/mL) 
THC Liquid chromatography 
HPLC-
Turboionspray 
source 
< 0.1 ng/mL 
Within 5% 
(at 2  
ng/mL) 
8 
(at 2 
ng/mL) 
 
 
Screening and semi-quantitation of benzodiazepines were 
performed by GC-ECD. 
 
A preliminary study on the therapeutic levels of different groups 
of drugs and their detectability (through the methodology and 
equipment followed and used by ESR) was performed. A wide 
range of prescription drugs could be detected at therapeutic 
levels [1,2]. The results are shown in Appendix 7. 
 
 
4.2.2 Statistical methodology 
The general project, of which this thesis is a part, is intended to 
analyse 2000 blood samples. It is expected that this number of 
cases will allow statistically robust inferences to be drawn about 
the significance of drug use in crashes.  
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Of the 240 samples that were collected and analysed during the 
research period, only 229 met the requirements for the 
culpability study and were included in this work. The reason for 
the exclusion of 11 cases was to avoid possible bias due to: the 
location of the accident (4 cases did not occur on the road) and 
drivers who were hospitalised (7 cases of drivers who received 
different drugs at the hospital). 
 
Selection bias was eliminated by including all drivers who died as 
a consequence of a car accident (the study frame consisted of 
deceased drivers). 
 
General descriptive statistics were performed in relation to: 
prevalence of drugs, age and gender. Culpable and not culpable 
groups were analysed in respect to the presence of alcohol alone 
(alcohol levels), cannabis alone and the combination of alcohol-
cannabis, time of accident and type of accident (single or 
multiple). Percentages were calculated from the total number of 
relevant cases (for every category). 
 
An approach to the responsibility analysis of cannabis use on 
driving impairment was carried out in this study. Cannabis was 
selected for this analysis due to its high incidence within the New 
Zealand population and its well known (Chapter 2) complexity in 
terms of concentration – effect relationship, which makes 
responsibility assessment through conventional methods (driving 
simulators and controlled driving areas studies) difficult. 
 
No power calculation was performed to evaluate the significance 
of the sample size since there was no background information 
supporting it (pilot study). However, at this stage in the study, 
the number of cases analysed is insufficient to enable statistically 
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robust conclusions and so only suggestions of risk and 
responsibility associated to drug use are possible.  
 
Odds ratio calculations were also done for alcohol and alcohol-
cannabis. The effect of alcohol on driving skills is well 
documented [3-6]. However, culpability analysis for other drugs 
was not possible due to the low number of positive cases at the 
completion of this thesis.  
 
The method used was designed by Drummer et al [7,8] and in 
this study was applied to New Zealand conditions. The design of 
such responsibility or culpability analysis is shown below (Table 
14) as are some practical examples.  
 
Categories and factors used in the assessment of the driver’s 
responsibility are known to be potentially contributory to a crash 
[9] and were selected on the basis of the information provided 
by the Police in the Police crash reports.  
 
The culpability assessment was conducted without knowledge of 
the toxicology results. Cross-correlation to the absence or 
presence of drugs and/or alcohol was completed subsequently. 
This arrangement is intended to avoid possible bias of the 
conclusions.  
  
 
The statistical test applied for the calculation of confidence 
intervals and p values, was Fisher’s exact probability test.   
 
 
 
 
 55
 
Table 14.  Design of the culpability study [7,8] 
Crash data analysis 
The analysis is based on information submitted by the Police including the 
post-mortem report from the pathologist. 
 
n  Information related to the circumstances of the car crash was extracted 
from the Police Fatal Crash report (Appendix 1).  
 
o Factual data relevant to the culpability assessment was classified in 
categories: 
 Condition of the road 
 Condition of the vehicle 
 Driving conditions 
 Type of accident 
 Witness observations 
 Road law obedience 
 Difficulty of task involved 
 Level of fatigue 
 
p  Every category was subdivided into factors, that had assigned a rank value 
depending on how contributory to the accident they are (Appendix 8 [7]) 
 
q  Every relevant factor was scored for 
each category. The scoring numbers 
range from 1 to 4, with 1 being not 
contributory and 4 contributory or 
mitigating factor for the category. 
 
The scores were then added and the 
result was multiplied by the total 
number of categories (8) and divided 
by the number of categories scored.   
 
In some cases not enough information 
was recorded in the Police report to 
allow scoring for each category. If less than 5 categories were able to be 
scored, the case was excluded from the analysis in order to prevent bias.         
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Table 14 continued 
Culpability or Responsibility analysis 
A blind analysis in relation to the presence of drugs was performed 
(unawareness of drug positive cases).  
 
n  Three groups of drivers were established depending on the following 
range of scores: 
 8 –12:   Culpable group (fatality due to driver performance) 
 13 – 15:  Contributory group (fatality due in part to driving 
conditions) 
 > 15:   Not culpable group (fatality due to factors other than driver  
            performance) 
 
Risk evaluation
 
n  Results from the toxicological analysis and results from the culpability 
analysis were cross-correlated in order to determine the responsibility of 
drug use in the causation of the accident. 
 
o  Calculation of the culpability ratio (CR) allows for the risk assessment of 
car accidents, based on the odds ratio (OR) method of Terhune [7,8,10] 
(culpable drivers/not culpable drivers, in relation to the presence and 
absence of drugs).  
 OR > 1:  higher risk of car accident, the significance of this 
association depends on the confidence intervals and p values. 
 The confidence percentage assumed was 95% 
 
 
  
            CR (drug+) 
OR =  
            CR (drug-)   
   
 
                           # of culpable drivers (drug positive)    
CR (drug+)  = 
                          # of not culpable drivers (drug positive)   
 
 
                           # of culpable drivers (drug negative)    
CR (drug-)  = 
                          # of not culpable drivers (drug negative)  
 
 
Drug negative, indicates the absence of any drugs including alcohol. 
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To illustrate the application of this methodology, some examples 
are given bellow: Fragments of the report (not originals) have 
been modified to preserve the confidentiality of the cases, 
however the information stated is true copy of the original. 
 
As in Study 1, identification details of the drivers included in 
Study 2 remained confidential. 
 
 
 Not culpable case example:  
Relevant details of the report are shown in Figure 5 and the 
score calculation in Table 15. Cannabis was detected in the 
blood sample of the deceased driver at a concentration of 4.6 
ng/mL. 
This is a case of a multiple vehicle crash in which the 
deceased driver was found not culpable for the accident. 
 
 
Figure 5. Report details (fragments) for the not culpable 
case example  
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Figure 5 continued 
 
 
 
 
 
 59
Table 15. Score calculation for the not culpable case 
example 
 
Category Factor Score 
Condition of the road 
Sealed- two or more lanes and 
smooth 
1 
Condition of the 
vehicle 
Roadworthy 1 
Driving conditions Day- clear and/or cloudy 1 
Type of accident 
Multiple- striking vehicle 
attempting to avoid 
2 
Witness observation Driver not to blame* 4 
Road law obedience Yes 3 
Difficulty of task 
involved 
Avoiding unexpected traffic or 
object 
3 
Level of fatigue - - 
Total 15 
Culpability score      15 x 8 / 7 17 
* Driver of the truck stated he did not see the motorcyclist when he pulled out. 
 
 
 
 Culpable case example:  
Relevant details of the report are shown in Figure 6 and the 
score calculation in Table 16. Cannabis was detected in the 
blood sample of the deceased driver at a concentration of 30 
ng/mL. 
This case corresponds to a multiple car crash in which the 
deceased driver was found culpable for the accident. 
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Figure 6. Report details (fragments) for the culpable case 
example  
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Figure 6 continued 
 
 
 
Table 16. Score calculation for the culpable case example  
Category Factor Score 
Condition of the 
road 
Sealed- two or more lanes and 
smooth 
1 
Condition of the 
vehicle 
- - 
Driving conditions Night- street no lighted 2 
Type of accident 
Multiple- Striking vehicle not 
attempting to avoid 
1 
Witness observation - - 
Road law obedience No 1 
Difficulty of task 
involved 
Straight road or sweeping bend 1 
Level of fatigue - - 
Total 6 
Culpability score      6 x 8 / 5 10 
 
 
 
 Contributory case example:  
Relevant details of the report are shown in Figure 7 and 
the score calculation in Table 17. Cannabis (2.3 ng/mL) 
and alcohol (80 mg/100mL) were detected in the blood 
sample of the driver.  
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This case corresponds to a single car crash in which the 
unfavorable driving conditions were found to have 
contributed partly to the accident. 
 
 
Figure 7.  Report details (fragments) for the contributory 
case example  
 
 
 
 
 
No crash diagram (drawing) was provided.  
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Figure 7 continued 
 
 
 
Table 17. Score calculation for the contributory case 
example  
Category Factor Score 
Condition of the road 
Sealed- two or more lanes and 
smooth 
1 
Condition of the 
vehicle 
Unroadworthy (contributing to 
accident) 
4 
Driving conditions Night- cloudy- road not lighted 3 
Type of accident 
Single- No influence from other 
vehicles 
1 
Witness observation - - 
Road law obedience No 1 
Difficulty of task 
involved 
Straight road or sweeping bend 1 
Level of fatigue - - 
Total 11 
Culpability score      11 x 8 / 6 15 
 
 
 
4.3 Discussion and Results 
 
4.3.1 General findings 
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Descriptive statistics of the 229 driver fatalities are shown next 
and a summary of the results is shown in Table 18.  
 
 A high proportion of male drivers, compared to the female 
group (about 3.5 times more) died on the road as a 
consequence of car crashes. Of the 229 samples analysed, 
78% (178) were from male drivers and 22% (51) were 
taken from female drivers.  
 
 Over half of the samples analysed, 55 % (125), gave 
positive results for drugs use (including alcohol) and 45% 
(104) tested negative. These figures show a high 
prevalence of drugs and alcohol use within the fatally 
injured drivers group. 
 
 The total number of positive drug cases (including alcohol) 
was 125, 82% (102) of which were male drivers and 18% 
(23) their female counterparts. This ratio is similar to the 
gender ratio for all fatally injured drivers. 
 
 Out of the 178 male, fatally injured drivers, 102 (57%) 
tested positive for drugs, of which 60 used single drugs 
and 42 consumed multiple drugs. 
 
 Of the fatally injured drivers aged 20-44, more had used 
drugs than had not. For the under 20 and over 45 year age 
groups drug use was less common (Table 19). 
 
 Of the 51 female fatally injured drivers, 23 (45%) tested 
positive for drugs. Similar figures were found for single and 
multiple drug consumption: 11 (48%) used single drugs 
and 12 (52%) a combination of drugs. 
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Single drug use 
 
 Of the 71 drivers who had used a single drug, alcohol was 
the most common drug being found in 45% (32) of the 
deceased drivers. A similar proportion of the male and 
female drivers had consumed alcohol. 
 
 Cannabis was the second most commonly detected drug 
being found in 38% (27) of the 71 drivers. Cannabis use 
was more prevalent in male drivers (93%, 25 drivers) than 
in female drivers (7%, 2 drivers).   
 
 Interestingly, methamphetamine was not detected in this 
group. 
 
 
Multiple drug use 
 
 The combination cannabis-alcohol was highly prevalent 
within the population analysed with 63% (34) of the 54 
cases.  
 
 Also important was the wide range of drug combinations 
that included legal and illegal substances. There was no 
information as to whether the legal drugs or medicines 
were prescribed or used for recreational purposes.  
 
A breakdown of the results by age and gender is shown in 
Appendix 9, general results are listed in Table 19 and the main 
findings are: 
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 Twenty six percent (33) of the 125 total positive cases fell 
in the group of drivers aged 25-34 years old. The incidence 
of drug use was significantly higher in this range of age 
(26/102 male and 7/23 female) with only 7 drivers not 
using drugs. 
 
 When alcohol or cannabis was used alone, it was equally 
distributed over drivers aged 15 – 64, oscillating between 
12 and 25% for alcohol and 15 and 22% for cannabis 
(Appendix 9). 
 
 Single usage of other drugs, such as paroxetine or 
fluoxetine was seen in the oldest group of drivers (45-
65+). It is very possible that they were medically 
prescribed. Benzodiazepines use was observed in drivers 
aged 25-44 years old. 
 
 The combination alcohol – cannabis was mainly seen within 
drivers in the range of 25-34 (35%, 12 cases) and 35-44 
years old (29%, 10 cases), in a lower proportion for drivers 
in the age of 15-24 years old (32%, 11 cases) and almost 
non-existent for drivers older than 45 years old (3%, 1 
case). 
 
 Another important combination was cannabis + alcohol + 
methamphetamine, found in the range of 25-34 years old 
for female drivers (2 drivers each aged 31 years old), and 
20-44 in the case of male drivers (1 driver aged 23 and 1 
driver 40 years old). 
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Table 18.  Drug use by gender for Study 2 
 
Gender 
Drugs 
Male Female 
Total 
Cannabis 25 
(93%) 
2 
(7%) 
27 
(38%) 
Alcohol 27 
(84%) 
5 
(16%) 
32 
(45%) 
Benzodiazepines 2 
(100%) 
- 
2 
(3%) 
Morphine 1 
(100%) 
- 
1 
(1%) 
Methamphetamine - - - 
Other drugs* 5 
(56%) 
4 
(44%) 
9 
(13%) 
S
in
g
le
 u
se
 
Total 60 
(84.5%) 
11 
(15.5%) 71 
Cannabis + alcohol 26 
(76.5%) 
8 
(23.5%) 
34 
(63%) 
Cannabis + benzodiazepines 1 
(100%) 
- 
1 
(2%) 
Cannabis + methamphetamine 1 
(100%) - 
1 
(2%) 
Other combinations** 14 
(78%) 
4 
(22%) 
18 
(33%) 
M
u
lt
ip
le
 u
se
 
Total 42 
(78%) 
12 
(22%) 
54 
Drug positive 102 
(82%) 
23 
(18%) 
125 
(55%) 
Drug negative 76 
(43%) 
28 
(55%) 
104 
(45%) 
Total 178 
(78%) 
51 
(22%) 
229 
*pseudoephedrine, paroxetine, fluoxetine, phenobarbital, solvents, dextropropoxyphen and 
ketamine. 
** alcohol+orphenadrine, methadone+THC, methadone+alcohol, valproate+THC, 
lignocaine+THC, BZP+THC, methadone+morphine+THC valproate+BD+alcohol, 
alcohol+THC+MA, morphine+THC+BD, MA+BD+THC, citalopram+THC+alcohol+MA, 
lignocaine+morphine+alcohol+THC and methadone+fluoxetine+THC+BD. 
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Table 19.  Number and percentage of drivers with and 
without drugs by gender and age categories for Study 2 
 
Age groups  (years old) 
Drug 
use 15-19 20-24 25-34 35-44 45-64 65 + Total 
Gender 
13 
(10%) 
18 
(14%) 
26 
(21%) 
24 
(19%) 
16 
(13%) 
5 
(4%) 
102 
(82%) Male 
1 
(1%) 
4 
(3%) 
7 
(6%) 
4 
(3%) 
5 
(4%) 
2 
(2%) 
23 
(18%) Female 
Positive 
14 
(11%) 
22 
(18%) 
33 
(26%) 
28 
(22%) 
21 
(17%) 
7 
(6%) 
125 Total 
11 
(10.5%) 
9 
(9%) 
6 
(6%) 
12 
(11.5%) 
29 
(28%) 
9 
(9%) 
76 
(73%) Male 
6 
(6%) 
4 
(4%) 
1 
(1%) 
2 
(2%) 
14 
(13%) 
1 
(1%) 
28 
(27%) Female Negative 
17 
(16%) 
13 
(12.5%) 
7 
(7%) 
14 
(13%) 
43 
(41%) 
10 
(10%) 
104 Total 
Total 31 
(13.5%) 
35 
(15%) 
40 
(17.5%) 
42 
(18%) 
64 
(28%) 
17 
(7%) 
229 Total 
 
 
Other statistical information related to the type of crash (multiple 
or single) and the time of the accident, in the presence or 
absence of alcohol, cannabis and the combination alcohol-
cannabis was extracted from this study and is summarized in 
Appendix 10. The general results are shown below: 
 
 Most of the accidents, where alcohol was involved, were 
single vehicle that often occurred against immobile objects 
(72%, 23 cases). A high number of these accidents took 
place in the early hours of the morning (37%, 12 cases 
between 12.01 and 6.00 am).  
 
 In the cases where cannabis alone had been used, 67% 
(18) of the cases were multiple car crashes. These crashes 
occurred all through the day but more commonly during 
daylight hours, from 6.00 am to 6.00 pm (37%, 18 cases). 
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 Drivers who used the combination cannabis – alcohol had a 
similar occurrence of single and multiple car accidents, 
41% (14) for multiple and 59% (20) for single crashes. 
Most of these accidents happen between 6.00 pm and 6.00 
am (79%, 27 cases). 
 
 75% (78) of drivers with no evidence of drugs in their 
blood were involved in multiple car crashes. These 
collisions occurred all through the day with a slightly higher 
tendency (as for cannabis) at night time from 6.00 am to 
6.00 p.m. 
 
 
4.3.2 Culpability analysis 
The results obtained after the analysis of the information 
registered in each fatal crash report and the scoring of culpability 
for every category, are shown in Table 20 and Table 21.  
 
 
Table 20.  General culpability results for alcohol, cannabis 
and their combination 
 
CULPABILITY 
DRUG USE 
Not 
culpable 
Contributory Culpable TOTAL 
GENDER 
2 1 24 27 Male 
Alcohol 
1 0 4 5 Female 
Total 3 1 28 32 Total 
5 0 20 25 Male 
Cannabis 
1 0 1 2 Female 
Total 6 0 21 27 Total 
2 1 23 26 Male Cannabis + 
alcohol 0 1 7 8 Female 
Total 2 2 30 34 Total 
Positive Total* 11 3 79 93 Positive Total 
15 4 56 75 Male Negative 
6 3 19 28 Female 
Negative Total 21 7 75 103 Negative Total 
TOTAL 32 10 154 196 TOTAL 
      * For alcohol, cannabis and their combination 
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Table 21.  General culpability results for other drugs and 
combinations 
 
CULPABILITY 
DRUG USE 
Not 
culpable 
Contributory Culpable TOTAL 
Benzodiazepines 1 0 1 2 
Morphine  0 0 1 1 
Other drugs* 1 0 7 8 
Cannabis + alcohol + 
methamphetamine 
0 0 4 4 
Other combinations** 3 1 12 16 
Positive Total*** 5 1 25 31 
       * pseudoephedrine, paroxetine, fluoxetine, phenobarbital, solvents, dextropropoxyphen and ketamine. 
              ** alcohol+orphenadrine, methadone+THC, methadone+alcohol, valproate+THC, lignocaine+THC, 
BZP+THC, methadone+morphine+THC valproate+BD+alcohol, morphine+THC+BD, MA+BD+THC, 
citalopram+THC+alcohol+MA, lignocaine+morphine+alcohol+THC and methadone+fluoxetine+THC+BD. 
       *** For the drugs in the table 
 
 
The results for the calculation of culpability ratios and odds ratios 
for cannabis, alcohol and their combination, as well as the 
confidence intervals and their p values are shown in Table 22.  
 
It was possible to assess the risk associated with different blood 
alcohol concentrations. However, there were not enough samples 
to do so for different blood THC levels in the cases of cannabis 
use. 
 
 
Risk and Responsibility 
 
 Drivers who had a car accident after consuming alcohol (all 
levels) were 2.6 times more likely to be culpable, 
compared to the group of people driving without drugs. 
The risk is almost doubled when the intake of alcohol is 
higher than 161 mg/100 mL (OR: 4.2). 
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 The use of cannabis alone does not seem to increase the 
risk of a car accident (OR: 0.98), it rather appears to be 
the same as for the negative drug use group (OR: 1.0). 
 
 The use of alcohol combined with cannabis quadruples the 
risk of being culpable for a car crash. This result is 
consistent with previous studies that have shown 
important driving impairment caused by this combination 
and elevated crash risk rates [4,5,11,12]. 
 
 
Significance 
 
Only the odd ratio for the concomitant use of cannabis and 
alcohol had a p value of less than 0.05 at which associations are 
considered statistically robust (Table 22).  The odd ratio for the 
alcohol category (total use) showed some statistical meaning but 
not enough to reach the conventional value for significance (p< 
0.05). 
 
Except in the case of the cannabis-alcohol category, the 
small sample size used for comparisons reflects lack of statistical 
significance (too small to represent the population and to give 
fair statistical significance). Therefore a larger statistical sample 
(like the 2000 samples originally set for Study 2) will reveal a 
better picture of the risk and responsibility of drug use prior 
driving. 
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Table 22.  Culpability assessment for alcohol, cannabis 
and their combination 
 
CULPABILITY 
DRUG USE 
Culpable 
Not 
Culpable 
Culpability 
Ratio 
Odds 
Ratio 
Confidence 
interval 
p value*
≤ 30 6 1 6 1.7 0.25 – 11.08 0.36 
31 - 80 - - - - - - 
81 – 160 7 1 7 2.0 0.29 – 12.73 0.32 
≥ 161 15 1 15 4.2 0.66 – 25.97 0.11 
Alcohol 
(mg/ 
100mL) 
Total 28 3 9.3 2.6 0.77 – 8.81 0.07 
Cannabis 21 6 3.5 0.98 0.36 – 2.66 0.21 
Cannabis + alcohol 30 2 15 4.2 1.02 – 17.0 0.028
**
Negative  75 21 3.6 1.0   
* Calculated using Fisher’s exact probability test 
** Statistically significant 
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5. Conclusions 
 
 
 
 
 
 Cannabis is without doubts, the most used recreational 
drug, after alcohol in the driver population of New Zealand. 
This tendency is reflected worldwide as different statistics 
and studies show use of this drug to be widespread within 
the general and the driver populations. 
 
  Cannabis is also the most used drug in combination with 
alcohol within the drinking driver population of New 
Zealand. 
 
 The concomitant use of cannabis with alcohol has a higher 
incidence of use within the fatally injured drivers, in 
comparison to each substance alone and other drug 
combinations. 
 
 High use of alcohol and drugs, especially cannabis, is 
evident in the youngest age group of drivers (uninjured 
drivers from fifteen to thirty four years old). 
 
 More male drivers die as a consequence of car crashes in 
New Zealand than female drivers. Likewise, cannabis use is 
more prevalent in the male (injured and uninjured) driver 
population. 
 
 At the moment, methamphetamine and MDMA use does 
not seem to be as significant, in terms of incidence within 
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the driver population, as cannabis, alcohol, cannabis and 
alcohol combined and benzodiazepines use. 
 
 Usage of other drugs (including morphine and heroin) 
individually or in combination does not seem to be 
substantial. However the wide range of combinations, 
including legal and illegal drugs, is important to be 
considered as represents a complex and dangerous 
menace on the roads. 
 
 Accidents involving alcohol seem to occur in a higher 
percentage as single car accidents in the early hours of the 
morning (from midnight to 6.00 am). 
 
 The culpability analysis approach shows an increased risk 
of accidents when alcohol (2.6 times) or the combination 
alcohol-cannabis (4.2 times) is present. However, only 
results for the latter (alcohol-cannabis) have statistical 
significance (p < 0.05). 
 
 Cannabis use does not seem to increase the risk or car 
crash occurrence, as the odds ratio for the group of drivers 
who tested positive for the drug, is similar to the free-drug 
group’s ratio. 
 
 The lack of statistical significance for most of the results of 
the culpability analysis, indicates the need for a larger and 
more representative sample from the fatally injured driver 
group. 
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5.1 Suggestions 
 
 A larger sample should be analysed to enable solid 
conclusions regarding the culpability or responsibility of 
drivers under the influence of drugs. The completion of 
Study 2 as part of the general project: “Drinking and 
drugged driver control: delineating the problem” will most 
probably allow for such reliable conclusions to be reached. 
 
 The inclusion of the seriously injured driver population into 
this project or a similar one, will broaden the current 
knowledge on drugs incidence and effects on driving 
performance. 
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Appendix 1. Police traffic crash report form 
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Appendix 1 continued 
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Appendix 1 continued 
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Appendix 1 continued 
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Appendix 1 continued 
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Appendix 1 continued 
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Appendix 2. Analytical and pre-analytical 
equipment used in studies 1 and 2 
 
 Equipment Brand/Model 
Autopipette (10-100 μL) 
and (100-1000 μL) Biohit 401640 and 4051761 
Autopipette multichannel 
(8 channels. 50-300 μL) Biohit 4033517 
Micropipette Brand Transferpettor 
Balance Mettler AE160 
Nitrogen blowdown Framo Geratetechick M 21/1 
Centrifuge Beckman GS-GR 
Vacuum concentrator Savant speed SVC-100H 
SPE work station Symark 50000/14 and 50000/2 
Plate washer 
Tecan Columbus plus art 
FLU9211 
Autovortex mixer Lab-line instruments 1291 
Multimixer Mistral lab-line 4600-1 
Rotary mixer Ratek RSM6 
Ultrasonic bath Cole-palmer 8850 
P
re
-a
n
a
ly
ti
ca
l 
 
Multi-block heater Lab-line instruments 2050-1 
GC-ECD 
Hewlett Packard 5890A with 
autoinjector 7673A 
GC-MS/NPD 
Agilent 6890A series plus +, MS 
and NPD detector Agilent 5973, 
autoinjector Agilent 7683. 
GC-MS Shimadzu QP2010 
LC-MS Shimadzu API 300 SCL 10AVP 
A
n
a
ly
ti
ca
l 
Plate reader Tecan Sunrise remote F03Y300 
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Appendix 3. ELISA methodology 
 
 
Reagents 
 
 Blank blood 
 Cut-off level standard 
 Buffer diluent 
 Labelled enzyme: horseradish peroxidase – drug derived 
 Chromogenic substrate: tetramethylbenzidine + urea 
peroxidase 
 Stop reagent: hydrochloric acid 1M 
 
 
Equipment 
 
 Ultrasonic bath 
 Autopipette multichannel 
 IMMUNALYSIS® direct ELISA kits: 
 -methamphetamine kit catalog 211-0480 
 -Cannabinoids (THCA/CTHC) kit catalog 205-0480 
 -Benzodiazepines kit catalog 214-0480 
 -Morphine specific kit catalog 213-0480 
 Plate washer 
 Micro-plate reader (450 nm).  
 
 
Methodology 
 
The methodology employed is shown in the scheme below. Every 
plate (96 wells) was set with a blank and a cut-off level standard 
every 22 samples. 
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Appendix 3 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leave @ room T 
for 1h (storage in 
fridge) 
Sonicate 
Dilute sample 
1:1 buffer 
Sample 
Dispense 40 μL into the 
center of the well 
Add 100 μL of labeled 
enzyme 
Incubate for 1h (30 min morphine) 
@ room T in the dark 
Add 100 μL of 
chromogenic substrate 
Wash wells thoroughly 
(plate washer) 
Incubate for 5-10 min. (5 min only 
morphine) @ room T in the dark 
Measure absorbance 
450 nm  
Add 100 μL of stop 
reagent 
development  of 
yellow colour: 
positive 
No change of 
colour (blue): 
negative 
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Appendix 4.  Breakdown of positive cases by gender 
and age for study 1, is included in Appendices 
(second part) 
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Appendix 5.  Breakdown of positive cases by age and 
alcohol levels for study 1 
 
 
AGE (years old) 
DRUGS Alcohol level 
(mg/100mL) 15–19 20– 24 25–34 35–44 45–64 65+ UK* Total 
≤ 30 9 
1% 
4 
1% 
- - 1 
0% 
- 2 
0% 
16 
2% 
31-80 47 
7% 
18 
3% 
8 
1% 
2 
0% 
1 
0% 
- 4 
1% 
80 
12% 
81-160 44 
7% 
91 
14% 
107 
16% 
82 
12% 
37 
6% 
- 1 
0% 
362 
55% 
≥ 161 14 
2% 
37 
6% 
73 
11% 
57 
9% 
20 
3% 
2 
0% 
- 203 
31% 
Cannabis 
Total 114 
17% 
150 
23% 
188 
28% 
141 
21% 
59 
9% 
2 
0% 
7 
1% 
661 
≤ 30 - 1 
3% 
- - - - - 1 
3% 
31-80 - - - 1 
3% 
- - - 1 
3% 
81-160 1 
3% 
- 3 
9% 
1 
3% 
5 
14% 
2 
6% 
- 12 
34% 
≥ 161 - 2 
6% 
1 
3% 
9 
26% 
7 
20% 
2 
6% 
- 21 
60% 
Benzodia-
zepines 
Total 1 
3% 
3 
9% 
4 
11% 
11 
31% 
12 
34% 
4 
11% 
- 35 
≤ 30 - - - 1 
13% 
- - - 1 
13% 
31-80 - - 1 
13% 
- - - - 1 
13% 
81-160 1 
13% 
2 
25% 
- 1 
13% 
- - - 4 
50% 
≥ 161 - - 1 
13% 
- 1 
13% 
- - 2 
25% 
Methamphe- 
tamine 
Total 1 13% 
2 
25% 
2 
25% 
2 
25% 
1 
13% 
- - 8 
≤ 30 - - - - - - - - 
31-80 - - - - - - - - 
81-160 - - - - - - - - 
≥ 161 - - - 1 
100% 
- - - 1 
100% 
In
d
iv
id
u
a
l 
u
se
 
Morphine 
Total - - - 1 
100% 
- - - 1 
≤ 30 - - 1 
5% 
1 
5% 
- - - 2 
10% 
31-80 - - 1 
5% 
- - - - 1 
5% 
81-160 - 1 
5% 
3 
14% 
3 
14% 
3 
14% 
- - 10 
48% 
≥ 161 - - 2 
10% 
2 
10% 
4 
19% 
- - 8 
38% 
Cannabis + 
benzodia-
zepines 
Total - 1 
5% 
7 
33% 
6 
29% 
7 
33% 
- - 21 
≤ 30 - - - - - - - - 
31-80 - 1 
8% 
- - - - - 1 
8% 
81-160 - 2 
17% 
3 
25% 
4 
33% 
- - - 9 
75% 
≥ 161 - - 2 
17% 
- - - - 2 
17% 
Cannabis + 
methamphe-
tamine 
Total - 3 
25% 
5 
42% 
4 
33% 
- - - 12 
≤ 30 - 1 
33% 
- - - - - 1 
33% 
31-80 - - - - - - - - 
81-160 - - 1 
33% 
1 
33% 
- - - 2 
67% 
≥ 161 - - - - - - - - 
M
u
lt
ip
le
 U
se
 
Other 
combinations
**
Total - 1 
33% 
1 
33% 
1 
33% 
- - - 3 
116 
16% 
160 
22% 
207 
28% 
166 
22% 
79 
11% 
6 
1% 
7 
1% Total 
* Unknown 
741 
** 1 driver with MA + BD, 1 driver with cannabis + morphine + MA and 1 driver with cannabis + morphine + BD 
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Appendix 6. Confirmatory methodologies for Study 
2 
 
 
Benzodiazepines screening and confirmation 
 
 
Reagents 
 
 Blank blood 
 Internal standard (prazepam)  
 Urea 8M 
 n-Butyl chloride (redistilled) 
 n-Butyl acetate (redistilled) 
 
Equipment 
 
 Silanised glass tubes 
 Ultrasonic bath 
 Autopipette  
 Autovortex mixer 
 Centrifuge 
 Vacuum concentrator 
 Multimixer 
 Autosampler vial with micro insert 
 GC-ECD 
 
Methodology 
 
The methodology employed is shown in the scheme below. It is a 
liquid-liquid extraction procedure followed by evaporation and 
reconstitution of the extract.  
 
Every set of samples is run with: 
 Standard (unextracted): mix of substances (triclosan, 
medazepam, oxazepam, diazepam, nordiazepam, 
flunitrazepam, nitrazepam, clonazepam and triazolam), used 
for evaluation of performance parameters (system suitability)  
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Appendix 6 continued 
 
of the equipment and retention times of commonly 
encountered benzodiazepines. 
 
 Blank blood : spiked with IS, used to evaluate the extraction 
recovery of all benzodiazepines.  
 
 Control (extracted): blood is spiked with zopiclone (0.10 
μg/mL) and used for evaluation of the extraction recovery of 
zopiclone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leave @ room To
for 1h (storage 
in fridge) 
Sonicate 
Mix for 10 min 
Sample 
0.2 mL dispensed 
into a glass tube 
Add 50 μL of internal 
standard 
Add 0.2 mL of urea 
Mix for 15 min 
Evaporate to dryness 
Centrifuge for 10 min 
Transfer butyl chloride layer to a 
clean tube 
Add 50 μL of n-butyl 
acetate 
Add 4 mL of butyl 
chloride 
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Appendix 6 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inject GC-ECD 
mix 
Transfer to an autosampler 
vial with insert  
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Appendix 6 continued 
 
 
Basic and neutral drugs screening and confirmation 
 
 
Reagents 
 
 Blank blood 
 Internal standard (proadifen)  
 Ammonia 50% 
 n-Butyl chloride (redistilled) 
 Ethanol 
 
Equipment 
 
 Silanised glass tubes 
 Ultrasonic bath 
 Autopipette  
 Autovortex mixer 
 Centrifuge 
 Vacuum concentrator 
 Multimixer 
 Autosampler vials with micro insert 
 GC-MS/NPD 
 
Methodology 
 
The methodology employed is shown in the scheme below. It is a 
liquid-liquid extraction procedure followed by evaporation and 
reconstitution of the extract.  
Every set of samples is run with: 
 Three sets of standards (unextracted): used for evaluation of 
performance parameters (system suitability) of the 
equipment and references for commonly used drugs. 
 
1) amphetamine, methyprylon, caffeine, clonidine, 
trimipramine, diazepam, amoxepine, papaverine,  
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Appendix 6 continued 
 
dextromoramide, triazolam, strychnine and I.S. (injected 
before starting any run and evaluated to ensure GC is 
operating up to specification) 
 
2) fluoxetine, methadone, amitriptyline, nortriptyline, 
dothiepin, diazepam, paroxetine, thioridazine and I.S. 
(injected before the run and between samples)   
 
3) cotinine, pethidine, lignocaine, carbamazepine, doxepin, 
citalopram and I.S. (injected at two concentrations after 
samples to provide reference standards).    
 
 Control (extracted): blood is spiked with a mix of substances 
(codeine, diazepam, dothiepin, methadone, 
methamphetamine, paroxetine and thioridazine), and used 
for evaluation of the performance of the extraction in terms 
of recovery percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leave @ room T 
for 1h (storage 
in fridge) 
Sonicate 
Mix for 10 min 
Sample 
0.2 mL dispensed 
into a glass tube 
Add 50 μL of 
internal standard 
Add 0.2 mL of 
ammonia 
Mix for 15 min 
Add 4 mL of butyl 
chloride 
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Appendix 6 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaporate to dryness 
Transfer butyl chloride layer to a clean tube 
Inject GC-MS/NPD 
Add 50 μL of ethanol 
mix 
Transfer to an autosampler 
vial with insert  
Centrifuge for 10 min 
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Appendix 6 continued 
 
THC confirmation and quantitation 
 
 
 
Reagents 
 
 Blank blood 
 Internal standard (D3-Δ9-THC)  
 Standard D0-Δ9-THC 
 Urea 8M 
 Pentane 
 Methanol:water (80:20) 
 
Equipment 
 
 Silanised glass tubes 
 Ultrasonic bath 
 Autopipette  
 Rotatory mixer 
 Centrifuge 
 Nitrogen blowdown 
 Autosampler vials with micro insert 
 LC-MSMS 
 
Methodology 
 
The methodology employed is shown in the scheme below. It is a 
liquid-liquid extraction procedure followed by evaporation and 
reconstitution of the extract.  
 
Every set of samples is run in triplicate, one of the samples is free 
of I.S. and the other two are spiked with the I.S. Every run 
includes: 
 Standard for the evaluation of the system suitability (D0-Δ9-
THC + I.S.), injected before the samples are run.  
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Appendix 6 continued 
 
 A set of unextracted standards of D0-Δ9-THC and I.S. at 0, 
0.5, 2.0, 5.0, 20.0 ng/mL, to build the calibration curve for 
quantitation 
 
 Control (extracted): 2.0 and 20 ng/mL of D0-Δ9-THC and I.S., 
used for evaluation of the performance of the extraction in 
terms of recovery percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The volume dispensed will depend on the total amount of blood sample available 
leave @ room T 
for 1h (storage 
in fridge) 
Sonicate 
Gently mix  
Sample 1 or  
0.5 mL* dispensed 
into a glass tube 
Add 5 μL 
of internal 
standard 
Add 1 mL of urea 
Cap and stand in the dark for 1h 
Add 6 mL of 
pentane 
Divide sample 
Sample 
no I.S. 
Sample  
+ I.S. 
Sample  
+ I.S. 
Gently mix for 
30 min 
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Appendix 6 continued 
 
 
 
 
 
 
Evaporate to dryness 
under nitrogen 
Transfer pentane layer to a clean tube 
Inject LC-MS-MS 
Add 50 μL of 
methanol:water 
mix 
Transfer to an autosampler 
vial with insert  
Centrifuge for 
15 min 
mix 
sonicate 
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Appendix 6 continued 
 
Morphine confirmation and quantitation 
 
 
 
Reagents 
 
 Blank blood 
 Internal standard (D3-morphine)  
 Morphine standard  
 Phosphate buffer (pH 3.3)  
 Distilled water 
 Methanol 
 Acetic acid (0.01M) 
 Ammonia in ethyl acetate (2%) 
 Dry ethyl acetate 
 Pentafluoropropionic anhydride (PFPA) 
 
Equipment 
 
 Silanised glass tubes 
 Ultrasonic bath 
 Autopipette  
 Centrifuge 
 SPE columns 
 SPE work station 
 Vacuum concentrator 
 Multi-block heater 
 Autosampler vials with micro insert 
 GC-MS 
 
Methodology 
 
The methodology employed is shown in the scheme below. It is a 
solid-liquid extraction (SPE) procedure followed by evaporation, 
derivatisation and reconstitution of the extract.  
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Appendix 6 continued 
 
Every set of samples is run in quadruplicate, one of the samples is 
free of I.S. and the other three are spiked with the I.S., every run 
includes: 
 A set of unextracted standards of morphine and I.S. at 0, 
20.0, 50.0, 100.0, 200.0 ng/mL, to build the calibration 
curve. 
 
 Spiked blood controls (extracted): 20 and 50 ng/mL of 
morphine and I.S., used for evaluation of the performance of 
the extraction in terms of recovery percentage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leave @ room T 
for 1h (storage 
in fridge) 
Sonicate 
Gently mix  
Sample 
0.2 mL dispensed 
into a glass tube 
Add 50 μL 
of internal 
standard 
Add 3 mL of 
phosphate buffer 
Cap and allow to equilibrate for 10 
min 
Divide sample 
Sample 
no I.S. 
Sample  
+ I.S. 
Sample  
+ I.S. 
Gently mix and 
sonicate for 15 min 
Sample  
+ I.S. 
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Appendix 6 continued 
 
 
 
 
 
 
 
 
Evaporate to dryness  
Transfer to workstation tubes 
Inject GC-MS 
Add 50 μL of dried 
ethyl acetate + 50 μL 
of PFPA 
Heat at 90 0C 
for 15 min 
Transfer to an autosampler 
vial with insert  
Centrifuge for 
10 min 
mix 
Elute through SPE 
columns in workstation 
Evaporate to dryness 
under nitrogen 
Add 50 μL of dried 
ethyl acetate  
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Appendix 6 continued 
 
Methamphetamine confirmation and quantitation 
 
 
 
Reagents 
 
 Blank blood 
 Internal standard (D3-methamphetamine, D3-amphetamine, 
D3-MDMA)  
 Methamphetamine, amphetamine and MDMA standards  
 Sodium hydroxide (10%)  
 Acid alcohol 
 n-Butylchloride (redistilled) 
 Dry ethyl acetate  
 Pentafluoropropionic anhydride (PFPA) 
 
Equipment 
 
 Silanised glass tubes 
 Ultrasonic bath 
 Autopipette  
 Centrifuge 
 Vacuum concentrator 
 Multi-block heater 
 Autosampler vials with micro insert 
 GC-MS 
 
Methodology 
 
The methodology employed is shown in the scheme below. It is a 
liquid-liquid extraction procedure followed by evaporation, 
derivatisation and reconstitution of the extract.  
 
Every set of samples is run in quadruplicate, one of the samples is 
free of I.S. and the other three are spiked with the I.S., every run 
includes: 
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Appendix 6 continued 
 
 Standards (unextracted) of methamphetamine, 
amphetamine, MDMA, aphedrine and pseudoephedrine at 
10.0 μg/mL. 
 
 Calibration curve (extracted): methamphetamine and MDMA 
and I.S.(deuterated standards) at 0, 0.05, 0.125, 0.25, 0.5 
and 0.75 μg/mL. 
 
 Spiked blood controls at approximately 0.05 and 0.2μg/mL of 
methamphetamine and MDMA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
leave @ room T 
for 1h (storage in 
fridge) 
Sonicate 
Gently mix  
Sample 
0.2 mL dispensed 
into a glass tube 
Add 50 μL 
of internal 
standard 
Add  50 μL  of NaOH 
Cap and allow to equilibrate for 15 
min 
Divide sample 
Sample 
no I.S. 
Sample  
+ I.S. 
Sample  
+ I.S. 
mix 
Sample  
+ I.S. 
Add  4 mL of  
n-Butylchloride 
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Appendix 6 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mix 
Centrifuge for 
10 min 
Evaporate to dryness 
with no heat  
Transfer n-Butylchloride layer to 
a clean tube 
Inject GC-MS 
Add 50 μL of dried 
ethyl acetate + 10 μL 
of PFPA 
Heat at 70 0C 
for 15 min 
Transfer to an autosampler 
vial with insert  
mix 
Evaporate to dryness 
under nitrogen at 400C 
Add 50 μL of dried 
ethyl acetate  
Add 50 μL of acid 
alcohol 
mix 
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Appendix 7. Prescription drugs detectability at 
therapeutic levels 
 
Drug 
Therapeutic 
concentration* 
(μg/mL blood) 
Detectability 
Sedative-hypnotic 
Nitrazepam 0.04 – 0.08 
Detect at 
therapeutic 
Temazepam 0.2 – 0.8 
Detect at 
therapeutic 
Triazolam 0.003 – 0.009 
Detect at 
therapeutic 
Zopiclone 0.07 – 0.1 
Detect at 
therapeutic 
Lormetazepam 0.006 – 0.016 
Detect at 
therapeutic 
Lorazepam 0.1 – 0.2 
Detect at 
therapeutic 
Antipsychotic 
Chlorpromazine 0.02 – 0.08 May not detect 
Prochlorperazine 0.001 – 0.003 Would not detect 
Olanzapine 0.01 – 0.03 
Detect at 
therapeutic 
Thioridazine 0.14 – 2.6 
Detect at 
therapeutic 
Clozapine 0.06 – 1.0 
Detect at 
therapeutic 
Quetiapine 0.05 – 0.7 May not detect 
Anxiolytic 
Diazepam 0.2 – 4.0 
Detect at 
therapeutic 
Clobazam 0.2 – 0.7 
Detect at 
therapeutic 
Alprazolam 0.03 – 0.1 
Detect at 
therapeutic 
Oxazepam 0.3 – 1.0 
Detect at 
therapeutic 
Medazepam 0.1 – 1.0 
Detect at 
therapeutic 
Anticonvulsant 
Carbamazepine 4.0 – 8.0 
Detect at 
therapeutic 
Phenytoin 10 – 20 Would not detect **
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Appendix 7 continued 
 
Drug 
Therapeutic 
concentration* 
(μg/mL blood) 
Detectability 
Anticonvulsant 
Phenobarbital 10 – 30 Would not detect **
Primidone 1 – 14 Would not detect **
Lamotrigine 1 – 4 Would not detect **
Clonazepam 0.03 – 0.08 
Detect at 
therapeutic 
Narcotic analgesic 
Dihydrocodeine 0.07 – 0.2 
Detect at 
therapeutic 
Methadone 0.08 – 0.8 
Detect at 
therapeutic 
D-propoxyphene 0.2 – 1 May not detect 
Tramadol 0.05 – 2.5 
Detect at 
therapeutic 
Pethidine 
(meperidine) 
0.1 – 0.5 
Detect at 
therapeutic 
Antidepressant 
Amitriptyline 0.04 – 0.16 
Detect at 
therapeutic 
Imipramine 0.008 - 0.105 
Detect at 
therapeutic 
Trimipramine 0.011 - 0.24 
Detect at 
therapeutic 
Nortriptyline 0.01 – 0.3 
Detect at 
therapeutic 
Dothiepin 0.02 – 0.42 
Detect at 
therapeutic 
Doxepin 0.005 – 0.115 
Detect at 
therapeutic 
Antidepressant 
Clomipramine 0.08 - 0.24 May not detect 
Citalopram 0.01 – 1.0 
Detect at 
therapeutic 
Maprotiline 0.2 – 0.7 
Detect at 
therapeutic 
Mianserin 0.03 – 0.06 Would not detect 
Nefazadone 0.4 - 2 Would not detect 
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Appendix 7 continued 
 
Drug 
Therapeutic 
concentration* 
(μg/mL blood) 
Detectability 
Antidepressant 
Paroxetine 0.01 – 0.06 May not detect 
Sertraline 0.02 – 0.05 May not detect 
Venlafaxine 0.2 
Detect at 
therapeutic 
Fluoxetine 0.02 – 0.4 
Detect at 
therapeutic 
Moclobemide 0.1 – 3 Would not detect 
Antihistamine 
Chlorpheniramine 0.05 – 0.02 May not detect 
Diphenhydramine 0.04 – 0.1 May not detect 
Cyclizine 0.05 – 0.1 May not detect 
Pheniramine 0.01 – 0.2 May not detect 
Promethazine 0.006 – 0.1 May not detect 
Trimeprazine 0.01 – 0.24 May not detect 
Anaesthetic 
Ketamine 0.05 – 0.2 ***
Detect at abuse 
levels 
 *  Approximate range of expected peak blood or plasma concentrations from  
     therapeutic use 
 ** Would not detect these drugs using the methods used in this study 
 *** Normal therapeutic levels mean patient is asleep 
 
Therapeutic levels from: Baselt, R.C., Disposition of Toxic Drugs and Chemicals in Man. 
seventh ed. 2004, Foster City, California: Biomedical publications, Baselt, R.C., Drug 
Effects on Psychomotor Performance. 2001: Biomedical publications. 
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Appendix 8. Scoring guidelines and contributory 
factors for the responsibility study of Study 2  
 
Category Factors Score 
Two or more lanes and 
smooth 
1 
Divided road 1 
Two or more lanes and 
rough 
2 
Unmarked, thin and 
smooth 
2 
Sealed road*
Unmarked, thin and rough 3 
Smooth 2 
1.  Condition of 
the road 
Unsealed road 
Rough and/or corrugated  3 
Roadworthy 1 
Unroadworthy (contribution unclear) 2 
2.  Condition of 
the vehicle 
Unroadworthy (contributory) 4 
Clear and/or cloudy 1 
Fog and/or mist, clear and 
windy**
2 
Visibility good and road 
wet**
2 
Day 
Showers and/or rain 3 
Clear**~  1 
Cloudy~ 2 
3.  Driving 
conditions 
Night  
Fog / mist / showers / rain 
/ ice / wind 
3 
No influence from other 
vehicles 
1 
Single 
Influence from other 
vehicles or objects 
3 
Striking vehicle attempting 
to avoid 
2 
Striking vehicle not 
attempting to avoid 
1 
Struck vehicle in the wrong 1 
4.  Type of 
accident 
Multiple  
Struck vehicle in the right 3 
No apparent reason 1 
Swerving 1 
Reckless 
Irregular driving 1 
Witnessed road 
infringement 
1 
Negligent 
Lack of road sense 1 
Vehicle fault 3 
5.  Witness 
observations 
Driver not to blame 4 
Yes 3 6. Road law 
obedience 
Obedience  
No  1 
Straight road or sweeping bend 1 
Heavy traffic 2 
Across lanes in 
Light traffic 1 
Winding road / sharp bend /U-turn 2 
Overtaking 2 
7.  Difficulty of 
task involved#
Avoiding unexpected traffic or object 3 
8.  Level of 
fatigue 
Level of fatigue 
If mentioned in Police 
reports 
2 
  * 1 point is added if the road has been recently resurfaced 
 ** 1 point is added if in heavy traffic 
 ~ 1 point is added if road not lighted 
 #  Score 1 if under the guidance of traffic signals 
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Appendix 9. Breakdown of positive cases by gender 
and age for study 2, is included in Appendices 
(second part) 
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Appendix 10. Additional information related to type 
and time of the accident for Study 2 
 
 
TYPE OF 
ACCIDENT 
TIME OF THE ACCIDENT 
DRUG 
Multiple Single 
12.01 am 
 –  
6.00 am 
6.01 am 
 –  
12.00 pm 
12.01 pm 
 –  
6.00 pm 
6.01 pm 
–  
12.00 am 
Alcohol 
9 
(28%) 
23 
(72%) 
12 
(37%) 
5 
(16%) 
8 
(25%) 
7 
(22%) 
Total 32 32 
Cannabis 18 
(67%) 
9 
(33%) 
3 
(11%) 
8 
(30%) 
10 
(37%) 
6 
(22%) 
Total 27 27 
Other 
drugs*
9 
(75%) 
3 
(25%) 
3 
(25%) 
3 
(25%) 
5 
(42%) 
1 
(8%) 
S
in
g
le
 u
se
 
Total 12 12 
Cannabis 
+ alcohol 
14 
(41%) 
20 
(59%) 
16 
(47%) 
3 
(9%) 
4 
(12%) 
11 
(32%) 
Total 34 34 
Cannabis 
+ alcohol 
+ MA 
- 4 
(100%) 
2 
(50%) - 
1 
(25%) 
1 
(25%) 
Total 4 4 
Other 
combina-
tions**
8 
(50%) 
8 
(50%) 
1 
(6%) 
4 
(25%) 
7 
(44%) 
4 
(25%) 
M
u
lt
ip
le
 u
se
 
Total 16 16 
Total 125 125 
Negative 
78 
(75%) 
26 
(25%) 
12 
(11.5%) 
33 
(32%) 
38 
(36.5%) 
21 
(20%) 
Total 104 104 
*pseudoephedrine, paroxetine, fluoxetine, phenobarbital, solvents, dextropropoxyphen, 
ketamine, morphine and benzodiazepines 
** alcohol+orphenadrine, methadone+THC, methadone+alcohol, valproate+THC, 
lignocaine+THC, BZP+THC, methadone+morphine+THC valproate+BD+alcohol, 
morphine+THC+BD, MA+BD+THC, citalopram+THC+alcohol+MA, 
lignocaine+morphine+alcohol+THC and methadone+fluoxetine+THC+BD. 
 
 
 A
p
p
e
n
d
ix
 4
.  B
re
a
k
d
o
w
n
 o
f p
o
sitiv
e
 ca
se
s b
y
 g
e
n
d
e
r a
n
d
 
a
g
e
 fo
r stu
d
y
 1
 
AGE (years old) DRUGS 
15 – 19 20 – 24 25 – 34 35 –44 45 – 64 65+ Unknown Total  
 95 
14% 
19 
3% 
138 
21% 
12 
2% 
162 
25% 
26 
4% 
124 
19% 
17 
3% 
46 
7% 
13 
2% 
2 - - 1 567 
86% 
88 
13% Cannabis 
114 
17% 
150 
23% 
188 
28% 
141 
21% 
59 
9% 
2 
0% 
7* 
1% 
 
661  
1 
3% 
- 1 
3% 
2 
6% 
3 
9% 
1 
3% 
5 
14% 
6 
17% 
9 
26% 
3 
9% 
3 
9% 
1 
3% 
- - 22 
63% 
13  
37% Benzodiazepines  1 
3% 
3 
9% 
4 
11% 
11 
31% 
12 
34% 
4 
11% 
- 35 
1 
13% 
- 2 
25% 
- 2 
25% 
- 1 
13% 
1 
13% 
- 1 
13% 
- - - - 6 
75% 
 
2  25% Methamphetamine 
1 
13% 
2 
25% 
2 
25% 
2 
25% 
1 
13% 
 - - 8 
- - - - - - 1 
100% 
- - - - - - - 
 
1 
 100% - 
S
i
n
g
l
e
 
u
s
e
 
Morphine 
- - - 1 
100% 
-  - - 1 
- - 1 
5% 
- 6 
29% 
1 
5% 
5 
24% 
1 
5% 
5 
24% 
2 
10% 
- - - - 17 
 
 81% 
4 
19% Cannabis + 
benzodiazepines 
- 1 
5% 
7 
33% 
6 
29% 
7 
33% 
 - - 21 
- - 3 
25% 
- 5 
42% 
- 4 
33% 
- - - - - - - 
 
12 
 100% - Cannabis + 
methamphetamine 
- 3 
25% 
5 
42% 
4 
33% 
-  - - 12 
- - 1 
33% 
- 1 
33% 
- 1 
33% 
- - - - - - - 
 3 
 100% 
- 
M
u
l
t
i
p
l
e
 
u
s
e
 
Other 
combinations**
- 1 
33% 
1 
33% 
1 
33% 
-  - - 3 
 97 
13% 
19 
3% 
146 
20% 
14 
2% 
179 
24% 
28 
4% 
141 
19% 
25 
3% 
60 
8% 
19 
3% 
5 
1% 
1 - 1 628 107 
14%  
 
 
 
85% Total 
116 
16% 
160 
22% 
207 
28% 
166 
22% 
79 
11% 
6 7* 741 
1% 1% 
       Male 
                                  Total    
       Female 
*     6 unknown gender cases and 1 unknown age (female). 
**   1 driver with MA + BD, 1 driver with cannabis + morphine + MA  and 1 driver with cannabis + morphine + BD 87
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a
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AGE 
DRUGS 
15-19 20-24 25-34 35-44 45-64 65+ TOTAL 
4 (12%) - 4 (12%) 
1 
(3%) 5 (16%) 1 (3%) 4 (12%) 
2 
(6%) 7 (22%) 
1 
(3%) 3 (9%) - 27 (84%) 5 (16%) Alcohol 
4 (12%) 5 (16%) 6 (19%) 6 (19%) 8 (25%) 3 (9%) 32  
         
 
 
5 
(18.5%) 
1 
(4%) 
6 (22%) - 6 (22%) - 
5 
(18.5%) 
- 3 (11%) 
1 
(4%) 
- -  25 (93%) 2 (7%) 
Cannabis 
6 (22%) 6 (22%) 6 (22%) 5 (19%) 4 (15%) - 27  
- - - - 1 (50%) - 1 (50%) - - - - - 2 (100%) - 
BD 
- - 1 (50%) 1 (50%) - - 2  
- - - - - - 1 (100%) - - - - - 1 (100%) - 
Morphine 
- - - 1 (100%) - - 1  
- - - - - - - - - - - - - - 
MA 
- - - - - - - 
- - 
1 
(12.5%) 
- 
1 
(12.5%) 
- - - 
1 
(12.5%) 
2 
(25%) 
2 (22%) 
2 
(22%) 
5 
(55.6%) 
4 
(44.4%) Other drugs*
- 1 (12.5%) 1 (12.5%) - 3 (37.5%) 4 (44.4%) 9  
9 (13%) 
1 
(1%) 
11 
(16%) 
1 
(1%) 
13 
(19%) 
1 
(1%) 
11 
(16%) 
2 
(3%) 
11 
(16%) 
4 
(6%) 
4 
(6%) 
2 (3%) 
60 
(84.5%) 
11 
(15.5%) 
S
i
n
g
l
e
 
u
s
e
 
TOTAL 
10 (14%) 12 (17%) 14 (20%) 13 (19%) 15 (21%) 6 (9%) 71 
3 (9%) - 5 (15%) 
3 
(9%) 
9 
(26%) 
3 (9%) 8 (24%) 
2 
(6%) 
1 (3%) - - - 26 (76%) 8 (24%) Cannabis + 
alcohol 
3 (9%) 8 (24%) 12 (35%) 10 (29%) 1 (3%) - 34  
- - - - 1 (100%) - - - - - - - 1 (100%) - Cannabis + 
MA - - 1 (100%) - - - 1  
- - - - - - 1 (100%) - - - - - 1 (100%) - Cannabis + 
BD - - - 1 (100%) - - 1  
1 (5.5%) - 2 (11%) - 3 (17%) 
3 
(17%) 
4 (22%) - 
4 
(22%) 
1 (5.5%) - - 14 (78%) 4 (22%) Other** 
combinations 
1 (5.5%) 2 (11%) 6 (33%) 4 (22%) 5 (28%) - 18  
4 (7%) - 7 (13%) 
3 
(5%) 
13 
(24%) 
6 
(11%) 
13 
(24%) 
2 
(4%) 5 (9%) 
1 
(2%) - - 
42 
(78%) 
12 
(22%) 
M
u
l
t
i
p
l
e
 
u
s
e
 
TOTAL 
4 (7%) 10 (18%) 19 (35%) 15 (27%) 6 (11%) - 54  
* pseudoephedrine, paroxetine, fluoxetine, phenobarbital, solvents, dextropropoxyphen and ketamine. 
** alcohol+orphenadrine, methadone+THC, methadone+alcohol, valproate+THC, lignocaine+THC, BZP+THC, methadone+morphine+THC 
val
       Male 
                                  Total    
       Female proate+benzos+alcohol, alcohol+THC+MA, morphine+THC+benzos, MA+benzos+THC, citalopram+THC+alcohol+MA, 108
           
